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ABSTRACT 
 
Joanna Antigone Walker 
 
 
EXPRESSION OF HUMAN PAPILLOMAVIRUS TYPE 16 E7 IS SUFFICIENT TO 
SIGNIFICANTLY INCREASE EXPRESSION OF ANGIOGENIC FACTORS BUT IS 
NOT SUFFICIENT TO INDUCE ENDOTHELIAL CELL MIGRATION  
 
Human papillomavirus 16 (HPV 16) causes cancer. Two viral oncoproteins of 
HPV 16, E6 and E7, are consistently expressed in these cancers. HPV 16 E6 and E7 
proteins target p53 and Rb family members, respectively, for degradation thus 
inactivating the functiond of these tumor suppressor proteins. Tumor development 
requires the acquisition of a blood supply, a process known as angiogenesis. Tumor 
suppressors negatively regulate angigogenesis. Expression of HPV 16 E6 and E7 together 
in human foreskin keratinocytes (HFKs) increases the level of angiogenic inducers 
vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8). Further, conditioned 
media from such cells are sufficient to alter endothelial cell behavior both in vitro and in 
vivo. To determine the individual contributions of HPV E6 and E7 to angiogenesis, 
translational termination linkers (TTLs) were inserted into the coding region of E6 or E7. 
Following retroviral transduction of the mutated cassette into HFKs, the ability of E7 in 
the context of the E6TTL mutation (E6TTLE7) and E6 in the context of the E7TTL 
mutation (E6E7TTL) to induce VEGF and IL-8 was compared to the LXSN control 
retrovirus. E7 and, to a lesser extent E6, increased the expression of VEGF and IL-8. 
Migration of human microvascular endothelial cells was not induced using conditioned 
media from either E6 or E7 expressing cells. Since the increased levels of VEGF and IL-
 vii 
8 induced by HPV 16E6ETTLE7 were not sufficient to alter endothelial cell behavior, 
immunological depletion experiments were used to determine whether either angiogenic 
factor was required for HPV 16E6 and E7 together to induce HMVEC migration. Only 
VEGF was required. Preliminary data suggest that the ability of HPV 16 E7 to induce 
angiogenic factors is dependent upon degradation of a specific Rb family member. 
    
                                                                          
Ann Roman, Ph.D., Chair 
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INTRODUCTION 
 
 
I. Human Papillomaviruses  
 
Human papillomaviruses (HPVs) are small double-stranded DNA viruses that 
infect mucosal and cutaneous stratified epithelia of the anogenital tract, head and neck, 
hands or feet (1, 106). The genomes of these viruses, which are approximately 8 kb, have 
virtually the same genomic organization, which can be divided into three main regions: 
the early, late and long control regions (1). The early region of the genome contains the 
open reading frames (ORFs) for the early proteins E1-E7, which are necessary for viral 
replication, transcription and cellular transformation (1). The late region, encodes the 
viral capsid proteins, L1 and L2 (Figure 1). The long control region (LCR), is neither 
transcribed or translated but contains a number of cis elements which are responsible for 
regulating viral transcription and replication (37). E5, E6 and E7 are considered the 
oncogenes although E5 is deleted in cervical cancer cells (149).  
 The HPV replication cycle is differentiation dependent and can be divided into a 
productive and non-productive stage. (37,106). Normally proliferation occurs in the basal 
cells and as they begin to migrate upwards these cells undergo differentiation and 
eventually exit the cell cycle. On the other hand, HPV infected suprabasal cells fail to 
exit the cell cycle. HPV genomes are established as extrachromosomal genomes, which 
replicate in synchrony with the cellular DNA. After cell division, daughter cells migrate 
into the suprabasal compartment, where uninfected keratinocytes undergoes terminal 
differentiation, while HPV-infected cells enter the S-phase of the cell cycle resulting in 
the production of infectious viral progeny (164). 
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Figure 1. Organization of the HPV 16 Genome.  
HPV 16 contains an approximately 8 kb circular double stranded DNA genome. 
The genome is divided into three basic sections: early (E1-E7), late (L1 and L2) and long 
control region (LCR). Adapted from (1). 
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II. Human Papillomaviruses and Cervical Cancer 
To date there are more than 200 types of HPVs that have been identified. These 
viruses can cause a wide range of diseases from benign genital warts to invasive cancer.  
There are 40 types that infect the mucosa and based on their oncogenic potential these 
viruses can be divided into two groups: high-risk HPV or low-risk HPV (117). The high-
risk HPV types such as HPV 16, 18, 31, 33 and 45 are mainly associated with the 
development of high-grade intraepithelial neoplasias of the anogenital tract, whereas low-
risk HPV types such as HPV 6 and 11 are mainly associated with low-grade 
abnormalities such as benign condyloma acuminatum or anogenital warts. The high-risk 
HPV type 16 and 18 are responsible for more than 70% of cervical cancer cases (120). 
Persistent infection with these high-risk types is thought to be a precursor to neoplastic 
transformation (120). 
 
III.  Biological Functions of E6 and E7 
The two early proteins of HPV 16, E6 and E7, play a significant role in tumor 
formation. E6 and E7 proteins are involved in cellular transformation (39, 140). Both in 
vitro and in vivo studies show that the functions of high-risk E6 and E7, of are necessary 
for the induction and maintenance of the transformed phenotype of cervical cancer cells 
by hijacking cellular pathways (13, 79, 113). The transforming properties of E6 and E7 
proteins result, in part, from their ability to modulate many host proteins that regulate cell 
growth and differentiation.  
HPV 16 E6, a small protein of approximately 150 amino acids, can localize to 
both the nucleus and cytoplasm of HPV infected keratinocytes (61). E6 contributes to 
cellular transformation by binding to and targeting p53 for ubiquitin-mediated 
4 
degradation (29, 147). p53 functions as a checkpoint for the integrity of cellular DNA 
before S-phase entry of the cell cycle. Normally, p53 is maintained at low levels and is 
inactive. Upon DNA damage or unscheduled induction of DNA replication, p53 is 
activated and this sends signals to the cell to undergo cell cycle arrest or apoptosis at the 
G1/S and G2/M checkpoints. The ability of p53 to initiate signaling pathways to trigger 
cell cycle arrest or apoptosis is thus lost in the presence of E6 and this allows for 
unscheduled replication of damaged DNA.  
E6 mediated degradation of p53 involves the E6 associated protein (E6-AP) 
(Figure 2). E6-AP functions as an E3 ubiquitin ligase and only in the presence of E6 can 
E6-AP ubiquitylate p53 so it can be recognized by the proteasome. E6 mutants, defective 
for binding to E6-AP but retaining p53 binding, are incapable of mediating p53 
degradation. Low-risk HPV E6 proteins bind p53 with a reduced affinity and do not 
participate in its degradation. Low-risk HPV E6 can bind to the p53 C-terminus but only 
high-risk HPV E6 has the ability to bind to the core region. Binding of the core region is 
required for p53 degradation by high-risk HPV E6 (30, 101).  
 High-risk E6 proteins also interact with a number of other host proteins.  For 
example, E6 has been reported to prevent apoptosis by inhibiting Bax gene expression in 
human keratinocytes (110). Inhibition of the Bax protein results in inhibition of apoptosis 
and therefore cells accumulate mutations in their DNA. High-risk E6 proteins also 
prevent apoptosis by binding to tumor necrosis factor receptor 1 (TNFR1) and inhibiting 
TNFR1 apoptotic signaling (46). Other cellular targets include Bak, Fas-associated death 
domain-containing protein (FADD) and procaspase 8, which is degraded by E6/E6AP  
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Figure 2. High-risk E6 targets p53 for degradation. 
 Normally, the level of p53 in normal cells is very low. In response to DNA damage, 
the level of p53 increases, induces downstream target p21 and sends signals to the cell to 
undergo cell cycle arrest or apoptosis. Degradation of p53 occurs through a complex 
containing E6 and E6-associated protein (E6AP). E6AP acts as an E3 ubiquitin ligase that 
ubiquitinates p53 and targets it for degradation by proteasome. 
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causing inhibition of apoptosis (56, 171). HPV E6 also downregulates the expression of 
Notch1 (167, 188). Decreased expression of Notch1 in cervical cancer cells contributes to 
tumorigenesis. HPV 16 E6 also activates nuclear factor kappa B (NF-κB) leading to 
enhanced expression of inhibitor of apoptosis 2 (IAP-2), which prevents apoptosis of 
epithelial cells (123). HPV E6 also binds and inactivates the transcriptional coactivators 
CBP and p300 (133, 195) which results in downregulation of transcription from the 
interleukin-8 promoter (77). 
 
A.  E6 Interaction with PDZ Domain proteins 
 E6 interaction with PDZ-domain-containing proteins, which are involved in cellular 
functions such as cell signaling and cell adhesion, leads to their degradation (81, 162, 
173, 184). Low-risk HPV E6 does not contain the PDZ-binding motif and therefore 
cannot PDZ-domain-containing proteins (172). Mutations within this motif result in a 
loss of the PDZ-binding ability of E6. Conversely, introduction of the PDZ-binding motif 
from a high-risk E6 into the C-terminus of a low-risk E6 protein results in gaining the 
ability to target and degrade PDZ domain proteins (55, 135). Interaction of E6 with 
numerous proteins contributes to E6 effectiveness in the promotion of HPV oncogenicity 
(178). 
 
B.  E7 Protein 
HPV 16 E7, a small nuclear protein of 98 amino acids, is best known for its 
association with the pocket proteins retinoblastoma protein (Rb), p107 and p130 (197) 
which regulate E2F transcription factors (51) (Figure 3). E2F transcription factors are 
heterodimers composed of E2F1-8, which are vital for regulation of G1 exit and S-phase  
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Figure 3. High-risk E7 targets Rb for degradation.  
Rb is active in its hypophosphorylated form and binds to E2F transcription factors 
to prevent S-phase entry. During the normal cell cycle, pRb is phosphorylated by cyclin 
D1/cyclin-dependent kinase 4 (CDK4) and cyclin E/CDK2 complexes causing 
dissociation of pRb from E2F thereby allowing S-phase progression. HPV E7 binds to the 
hypophosphorylated pRb, preventing its interaction with E2F. Therefore, the checkpoint 
Control at G1/S transition is lost and the cells continually traverse the cell cycle leading 
to uncontrolled proliferation. 
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progression. In uninfected cells, Rb is hypophosphorylated in early G1 and bound to E2F   
transcriptional factors 1-3, repressing their transcriptional activity. Upon phosphorylation 
triggered by CDK4/6 and CDK2, the complex dissociates, allowing these E2Fs to act as a 
transcriptional activators. Association of E7 with hypophosphorylated Rb, prevents its 
binding with E2F, thereby promoting uncontrolled cell cycle progression (21). 
Additionally, E7 ubiquitin-mediated degradation of Rb involves association and 
reprogramming of the cullin-2 ubiquitin complex (78). Low-risk HPV E7 binds to Rb 
family members with lower affinity than the high-risk HPV 16 E7 (22, 54, 119). For Rb 
binding, this difference is due to an Asp 21 in HPV 16 E7 compared to a Gly 22 in HPV 
6E7 (69, 144).  
 
C.  E7 Interaction with Cyclin-dependent Kinase Inhibitors 
E7 has been shown to interact with various cellular targets. For example, E7 
interaction with cyclin-dependent inhibitors p21Cip1 and p27KIP1 abrogates their growth 
inhibitory activities (53, 82, 190), which are induced in various ways such as through 
activation of p53 and anti-proliferative signals (41). Interestingly, the steady state levels 
of p21CIP1 are increased during differentiation of keratinocytes and, through some 
unknown non-transcriptional mechanism in the presence of E7.  
 
D.  E7 Interaction with Histone Deacetylases (HDACS) 
E7 interactions with HDACs, which function as corepressors by chromatin 
remodeling, results in an increase in the level of E2F2- mediated transcription in 
differentiating cells (107). Other E7 binding partners include members of the AP1 family, 
which play a role HPV transcription (58, 74, 169). AP-1 binding sites are found in the 
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regulatory regions of both high-risk and low-risk HPVs. Also, E7 can directly or 
indirectly interact with histone acetyl transferases (86), including p300, pCAF and steroid 
receptor coactivator-1 (SRC1) (7, 77). 
 
IV. RNA Splicing Regulates E6 and E7 Expression 
 RNA splicing is necessary for gene expression and vital during the papillomavirus 
life cycle. In a natural infection, HPV 16 E6 and E7 are transcribed as a single bicistronic 
transcript (Figure 4). The p97 promoter is positioned upstream of the E6 open reading 
frame and its role is to initiate transcription of E6 and E7. Within the E6 coding region 
there is one 5’ splice donor (226) and three alternative 3’ splice acceptors (409, 526, and 
742). Unspliced mRNA is translated into E6. mRNA spliced from nt 226 to nt 409 E6 is 
referred to as E6*I and encodes a truncated E6 protein called E6*I. Splicing from nt 226-
526 created truncated E6*II and splicing from nt 226 to 742 creates truncated E6*III  
(Figure. 4). The majority of transcripts within cancer tissues and cervical cancer cell lines 
produce E6*I (15, 38, 152, 193, 194). Splicing depends on the distance of the splice 
donor from the promoter (194). Translation of E7 is dependent upon splicing (194). The 
distance between the termination of E6 translation and the reinitiation of E7 translation is 
2 nucleotides. E6*I contains a premature codon immediately downstream of the splice 
junction creating enough space for termination of E6 translation and the reinitiation of E7 
translation (93) therefore benefiting the expression of E7.  
Splicing is inefficient in the context of the retrovirus, L(16E6E7)SN, encoding 
HPV 16E6E7 within the LXSN retrovirus. E6 and E7 expression is dictated not by the  
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Figure 4. Diagram of splice message within HPV 16 versus unspliced message within 
the retrovirus HPV 16E6E7.  
 Exons are represented as boxes and introns are lines between the boxes. Numbers 
above the ORFs are nucleotide positions for each viral gene. Dashed lines from 5’ splice 
site indicate the splice acceptor for each 3’splice site. The arrows below the bicistronic 
transcript are primers used for RT-PCR analysis in Chapter 1. The lower schematic 
shows the unspliced and spliced mRNA and corresponding encoded protein.  
P97 promoter but by the retroviral long terminal repeat (LTR). The mRNA in cells 
infected with the retrovirus undergoes splicing less frequently due to the distance 
between the LTR and initiation of E6 transcription (194).  
11 
V.  Angiogenesis and Tumor Suppressors 
The establishment and maintenance of a vascular supply is required for growth of 
malignant tissue. Consistent with this, progression of the pre-malignant stages to invasive 
cervical cancer is associated with the development of new blood vessels. Angiogenesis is 
the recruitment of new blood vessels by extension of preexisting vasculature (16, 48). 
Angiogenesis is crucial for a developing tumor to acquire nutrients and oxygen for 
sustained growth and expansion (16).  
Angiogenesis is tightly regulated by several secreted factors. According to the 
current model of angiogenesis, vessels seen in normal tissue are quiescent due to the 
presence in the microenvironment of elevated levels of angiogenic inhibitors such as 
thrombospondin-1 and maspin, relative to angiogenic inducers, such as VEGF and IL-8 
(16, 67)(Figure 5). As cells progress towards tumorigenicity, the balance between 
angiogenic inducers and angiogenic inhibitors switches, such that angiogenic inducers 
dominate. This may occur by several mechanisms: cells may decrease the amounts of 
angiogenic inhibitors being secreted while continuing to secrete the same amounts of 
inducers, cells may increase the amounts of angiogenic inducers being secreted while 
continuing to secrete the same amounts of inhibitors, or both events may occur.  
In tumor cells, a link between the functions of tumor suppressors and 
angiogenesis has long been established (59). Following HPV 16 infection, the E6 and E7  
oncoproteins are consistently expressed. This results in disruption of the normal function 
of tumor suppressors, p53 and pRb, leading to unrestricted cell cycle entry and 
deregulated proliferation of the infected cell but also alteration in expression of 
angiogenic factors and induction of angiogenesis (23, 177).  
12 
 
 
 
 
 
 
 
 
 
Figure 5. Current Model of Angiogenesis.  
In quiescent or normal tissue, inhibitors of angiogenesis predominate and the 
angiogenic switch is off. Angiogenesis can be achieved by increase of inducers and/or 
decrease of inhibitors such that the balance is tipped in favor of a pro-angiogenic 
phenotype i.e angiogenesis is turned on. The circles represent angiogenic inhibitors and 
boxes represent angiogenic inducers. 
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VI.  Regulation of Angiogenic Factors 
There are a number of factors that have been known to induce angiogenesis (16,  
25). Among the known factors, vascular endothelial growth factor (VEGF) serves as a  
major regulator of the angiogenic processes and has been the center of numerous 
investigations. The VEGF family of glycoproteins is composed of VEGF-A, VEGF-B,  
VEGF-C, VEGF-D, and placenta growth factor (PIGF). VEGF-A, also known as  
vascular permeability factor (VPF), has four main isoforms (VEGF121, VEGF165,  
VEGF189, and VEGF206) produced by alternative splicing (75, 175). A fifth isoform  
VEGF145is found within the reproductive tract of females, and has also been found in  
placenta and carcinoma cells. VEGF189 and VEGF206 are the most abundant forms. 
VEGF189 is present throughout the tissues, whereas VEGF206 is only found in embryonic  
tissue. Both are sequestered in the extracellular matrix. VEGF165 and VEGF121 are the  
most frequently secreted, however, VEGF165 is the mature isoform (98). 
VEGF stimulates migration and proliferation of microvascular endothelial cells  
derived from arteries, veins, and lymphatic vessels (45) as well as angiogenesis in vivo  
and in vitro. For example, Phillips, et al. reported (134) that VEGF stimulated direct  
angiogenesis in the rabbit cornea. Similarly, Tolentino, et al. (176) reported that VEGF  
was sufficient to produce iris neovascularization and neovascular glaucoma in  
primates. VEGF also induces lymphangiogenic responses in mice (122). When serum is  
lacking, VEGF prevents apoptosis of endothelial cells in vitro (57). Cells of many human  
solid tumors express large amounts of VEGF protein, thus stimulating the development  
of new blood vessels within the developing tumor. 
Hypoxia plays a major role in regulating the expression of VEGF in both 
malignant and normal cells (114, 154). The response of VEGF to hypoxia is primarily  
regulated through the activity of the transcription factor hypoxia-inducible factor-1 (HIF- 
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1). HIF-1 is composed of two subunits, HIF-1α and HIF-1β; only HIF-1α is regulated by  
low oxygen tension (10, 18). Under normoxia, two prolyl residues (Pro402 and Pro562) of  
the HIF-1α subunit are hydroxylated by oxygen-dependent prolyl hydroylases. The  
hydroxylated protein is targeted for degradation through its interaction with the von- 
Hippel-Lindau (VHL) proteasome pathway (42). 
During hypoxia, prolyl hydroxylation is inhibited, blocking VHL-mediated  
degradation, resulting in the accumulation of HIF-1α within the cell. This in turn  
activates expression of HIF-1 target genes including VEGF (10, 179). Knocking out  
HIF-1α results in embryonic lethality due to impaired vascular formation (143). 
The expression of VEGF is also enhanced by a number of factors independent of  
hypoxia and HIF-1α. For example growth factors such as epidermal growth factor (71),  
transforming growth factors (TGFα and TGFβ), insulin-like growth factor 1 (IGF-1),  
fibroblast growth factors (FGF), platelet-derived growth factors (PDGF) all may regulate  
VEGF expression possibly through an autocrine or paracrine effect (43, 125). In addition  
to growth factors, oncogenes have also been known to induce expression of VEGF.  
Oncogenic ras and myc, major regulators of angiogenesis, regulate expression of VEGF  
(12, 138, 182) under in vitro and in vivo conditions.  
A link between VEGF and the progression of disease in HPV 16 transgenic mice  
and in cervical carcinogenesis has been shown (155). E6 and E7 proteins of high risk  
HPVs affect proteins known to regulate angiogenesis. E6 under some conditions can  
increase expression of c-myc and under other conditions can target c-myc for degradation  
(87).  Both E6 and E7 are required for maintenance of c-myc expression (33). E6 and E7  
can enhance the expression of VEGF (23) through many possible mechanisms. VEGF  
expression can be regulated by NFκB and activator protein -1 (AP-1). E6 has been  
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reported to transactivate genes via NFκB and E7 can enhance AP-1 mediated  
 
transactivation (3, 36).   
Interleukin-8 (IL-8), which is produced by macrophages, is another important 
mediator of tumor-derived angiogenesis. IL-8 is normally secreted in response to growth 
factors, inflammatory cytokines, and pathophysiologic conditions (94, 183, 186). The 
increased expression of IL-8 correlates with amplified neovascularization density (109, 
187)as well as an increase in tumor growth (109). IL-8 expression was first discovered in 
malignant melanoma cell lines, and IL-8 expression is considered to play a role in 
regulating the growth and metastasis of melanoma (189). The ability of IL-8 to increase 
levels of matrix metalloproteinase-2 (MMP-2), which degrades the extracellular  
basement membrane and remodels the extracellular matrix (ECM), initiates the early 
phase of tumor angiogenesis (89). IL-8-transfected melanoma cells displayed increased  
levels of MMP-2, while transfection of identical melanoma cells with VEGF and bFGF 
did not affect MMP-2 levels (88), which demonstrated that IL-8 is important for tumor-
induced angiogenesis. Endogenous expression of IL-8 has also been detected in 
numerous human cancers including breast cancer (62), colon cancer (19), ovarian cancer 
(11), prostate cancer (181) and cervical cancer. IL-8 was found to be upregulated in oral  
squamous cell carcinomas and to be affected by HPV gene expression (105, 177). 
 IL-8 has been shown to induce proliferation and chemotaxis of human umbilical 
vein endothelial cells (HUVEC) and human aortic endothelial cells (91, 166). IL-8 has 
also been shown to stimulate both endothelial proliferation and capillary tube formation 
in vitro; the effect can be reversed using neutralizing antibodies to IL-8 (153, 180).  
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Figure 6.  The VEGF promoter: response elements to trans-activating factors. 
The entire region of the VEGF promoter is represented. The heavy arrow 
indicates the classical initiation site of transcription, whereas the light arrow indicates the 
position of the cryptic promoter present in a domain of the gene described as the 5′ 
untranslated region of the VEGF mRNA. 
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 The 5’ flanking region of the IL-8 gene is sufficient for transcriptional regulation of 
IL-8 gene expression (68, 115). The IL-8 promoter contains binding sites for AP-1, 
nuclear factor kappa B (NFκB) and CAAT/ enhancer-binding protein (C/EBP).  NFκB 
induction is necessary for the induction of IL-8 expression and both NF-κB and AP-1 
sites have been shown to be responsible for expression of IL-8 in certain cancers (96).  
As noted earlier, E6 and E7 can activate these transcription factors (3, 36). In all, IL-8 
expression in cancer cells and the tumor microenvironment plays a vital role in enhancing 
tumor progression. 
 
VII.  Tumor Microenvironment and Angiogenesis 
Angiogenesis is crucial for tumor development. Solid tumors cannot grow beyond 
a few millimeters without a sufficient blood supply (49). As stated previously, 
angiogenesis depends on a balance between angiogenic inhibitors and inducers. During  
tumor progression, this balance is tipped favoring proangiogenic events and the 
angiogenic switch is turned on.    
The tumor microenvironment contains a mixture of extracellular matrix (ECM) 
proteins, tumor cells, endothelial cells, fibroblasts and immune cells that turn the 
angiogenic switch on. The extracellular matrix provides structural support to cells and 
tissues, transmits signals through receptors, and binds and stores growth factors and other  
active molecules. Basement membranes (BM) are ECM that function as barriers, polarize 
cells, shape tissue structures and support migrating cells (65). Vascular BM support blood 
vessel endothelial cells (84) and modulate endothelial cell behavior (31). 
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Figure 7. The IL-8 promoter.  
The entire region of the promoter is represented. The heavy arrow indicates the  
classical initiation of transcription. 
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Many ECM proteins, such as collagens and laminins, have proangiogenic 
properties. They help promote endothelial cell survival, proliferation and migration (127). 
Many pro-angiogenic factors such as VEGF, basic fibroblast growth factor (bFGF) and 
transforming factor beta (TGF-β) are sequestered in the ECM and can be mobilized 
during ECM degradation by proteases secreted by tumor or stromal cells (159). 
Fibroblasts regulate ECM degradation, epithelial differentiation and behavior, 
inflammation, wound healing and cancer progression. Stromal fibroblasts, carcinoma-
associated fibroblasts (CAFs) or tumor-associated fibroblasts (TAFs) have the ability to 
promote tumor growth (85, 131). Olumi, et al. showed that CAFs have tumor promoting 
ability in prostate carcinomas (129). CAFs from invasive breast carcinomas promote the 
growth of mammary carcinoma cells and enhanced tumor angiogenesis (130).  
CAFs secrete elevated levels of stromal cell-derived factor (SDF-1), which plays 
a vital role in the promotion of tumor growth and angiogenesis. SDF-1 produced by 
immune cells also induces VEGF in endothelial cells (73). VEGF induces vascular 
permeability resulting in an influx of endothelial cells, fibroblasts and inflammatory cells 
(20). Fibroblasts are the main source of VEGF in tumors (52). Fibroblasts are involved in 
the production and storage of latent VEGF in the extracellular environment.  
 Chronic inflammation is associated with most cancers. The immune cells play a 
dual role in cancer progression (96). On the one hand the immune system is capable of 
recognizing and attacking cancer cells. On the other, evidence suggests that cancer 
associated inflammation promotes tumor growth and progression. The cancer associated 
inflammation starts with migration and infiltration of leucocytes from the blood stream to 
the site of inflammation followed by the infiltration of monocytes, plasma cells and 
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lymphocytes. Tumor cells produce a variety of growth factors, cytokines and 
chemokines, such as VEGF, bFGF and PDGF that attract leucocytes and stimulate 
migration of mast cells. 
The link between chronic inflammation, premalignant progression, tumor growth 
and metastasis has been shown. Arbeit, et al. and Coussens, et al. utilized a transgenic 
mouse model of multistage epithelial carcinogenesis. In this model the early genes of 
HPV 16 were expressed under the control of the human keratin 14 (K14) promoter to 
produce (K14-HPV 16) transgenic mice(5, 25). Despite transgene driven oncogene 
expression in keratinocytes, the absence of mast cells or the lack of innate immune cell 
recruitment to premalignant skin prevents neoplastic progression. Secretion of IL-8 by 
xenograft tumor cells is required for RasV12-dependent tumor-associated inflammation, 
tumor vascularization and tumor growth (161). Depletion of granulocytes abolishes 
angiogenesis of RasV12-expressing tumors, therefore suggesting that the recruitment of 
granulocytes by neoplastic cells facilitates tumor growth (161).   
 Macrophage infiltration is critical in the wound healing process. When tissue 
damage occurs, macrophages infiltrate the wound to participate in the repair process. 
Macrophages aid in tissue matrix remodeling, cell growth and angiogenesis (112). One 
important inflammatory cell type found in the stroma of the tumor is the tumor-associated 
macrophage (TAM) (8). TAMs have an important role in tumor progression by exerting 
their immune functions in tumor cell proliferation, tumor cell invasion and tumor 
angiogenesis. TAMs are found in precursor lesions of cutaneous melanoma, squamous 
and cervical carcinoma, and mammary adenocarcinoma (27, 90, 104). Precursor lesions 
containing elevated numbers of TAMs may sabotage normal macrophage associated 
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processes and aid with the invasion of neoplastic cells into the surrounding stroma (104).  
 The proangiogenic function of TAMs has been demonstrated in vivo. In polyoma  
 
virus middle T oncoprotein (PyMT)-induced mouse mammary tumors, macrophages 
were recruited to the lesions (100). Depletion of macrophages in PyMT-induced tumors 
decreased vascular density(100). Bingle et al. showed that by using a mouse dorsal 
skinfold chamber model, which allowed in situ visualization and monitoring of implanted 
tumor spheroids and the surrounding blood vessels in vivo, macrophages in tumor 
spheroids increased VEGF release and significantly enhanced angiogenesis (14). 
 TAMs serve as the main source for chemokines, growth factors, cytokines and 
proteases that regulate endothelial cells in the tumor microenvironment (28, 136). Studies 
using MCP-1-expressing tumor cells indicate that low levels of monocyte chemotactic 
protein-1 (MCP-1) have a modest effect on macrophage recruitment and enhanced 
angiogenesis and tumor growth in melanoma xenograft models (124). In contrast, 
elevated levels of MCP-1 induce more extensive macrophage infiltration, resulting in 
robust angiogenic reponses, enhanced tumor growth and tumor regression (124).  
 Growth factors, including vascular endothelial growth factor (VEGF), basic  
 
fibroblast growth factor (bFGF), epidermal growth factor (71)(71), and transforming 
growth factor-α (TGF-α), are known to be produced by TAMs. Among them, VEGF can 
promote endothelial cell growth, maturation and survival (44). VEGF functions as a 
monocyte chemotactic factor to attract TAMs to the hypoxic areas of tumor (99, 121).
 Inflammatory cytokines have been known to participate in macrophage-associated 
angiogenesis during wound healing (95, 165). IL-8 is a mitogen of endothelial cells and 
stimulates angiogenesis (76). The conditioned media of macrophages has been shown to 
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have similar effects and the effects can be abolished by neutralizing antibodies to IL-8, 
suggesting that IL-8 produced by macrophages plays a role in macrophage-associated 
angiogenesis (91). Tumor necrosis factor-α (TNF-α) is also involved in macrophage-
associated angiogenesis. When overexpressed in endothelial cells, TNF-α was growth-
inhibitory and cytotoxic to endothelial cells (141, 146). In contrast, exogenous TNF-α 
promoted formation of new blood vessels in several in vivo models (50). Leibovich, et al. 
(97) further showed that anti-TNF-α antibodies neutralized angiogenic activity in the 
conditioned media of activated macrophages, supporting the role of TNF-α as an 
angiogenic molecule from macrophages (97).  
 Other inflammatory cells such as mast cells, neutrophils and eosinophils contribute 
to angiogenesis (28). Mast cells are able to promote angiogenesis in squamous cell 
epithelia (26). In a mouse model of pancreatic islet carcinogenesis, neutrophils and 
macrophages are the main source of matrix metalloproteinase-9 (MMP-9) and thus 
mediate the angiogenic switch. Furthermore, depletion of neutrophils affected the 
association of VEGF with its receptor. Thus neutrophils play a crucial role in activating 
the angiogenic switch during early carcinogenesis (126). 
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VIII.  Present Studies 
The Roman laboratory has shown that expression of HPV 16E6E7 together in 
human foreskin keratinocytes (HFKs) increases the level of two angiogenic inducers 
VEGF and IL-8(177). Further, conditioned media from such cells are sufficient to alter 
endothelial cell behavior(23). Experiments were designed to determine the individual 
contributions of E6 and E7 to this process. Translational termination linkers (TTLs) were 
introduced into the coding region of E6 or E7. The ability of E7 in the context of the 
E6TTL mutation (E6TTLE7) and E6 in the context of the E7TTL mutation (E6E7TTL) 
to induce VEGF and IL-8 was examined. Both VEGF and IL-8 were significantly 
enhanced in HFKs expressing either HPV 16E6TTLE7 or HPV 16E6E7TTL. Migration 
assays revealed that neither E6 nor E7 induced migration of human microvascular 
endothelial cells (HMVECs). Immunological depletion experiments showed that only 
VEGF was required for HPV 16E6E7 together to induce HMVEC migration. These 
studies shed light on the contribution of the E6 and E7 viral oncoproteins and the 
angiogenesis required for the development of cervical cancer and may further help us 
better understand how to manage HPV-induced disease.  
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MATERIALS AND METHODS 
 
I.  Cell Cultures  
 
A. Human Foreskin Keratinocytes (HFKs)  
Primary human foreskin keratinocytes were prepared from newborn male 
foreskins obtained from Wishard Hospital. Keratinocytes from individual foreskins were 
plated onto mitomycin C (Sigma)-treated 3T3-J2 fibroblasts 10 cm plates. The cells were 
maintained in E medium [3 parts Dulbecco’s modified Eagle’s medium (DMEM)/1 part 
Ham’s F-12 supplemented with 10% fetal bovine serum (FBS) (Thermo Scientific), (50 
mg/ml, Sigma) gentamicin, (100 U/ml, Invitrogen) penicillin/streptomycin, (24 µg/ml, 
Sigma) adenine, (.4 µg/ml, Sigma) hydrocortisone, (50 µg/ml, Sigma) transferrin, (2 nM, 
Sigma) 3,3’-5-triodo-L-thyronine, (5 µg/ml, Sigma) insulin, (10 µg/ml, Invitrogen) EGF 
and (10 µg/ml, Sigma) cholera toxin.  At approximately 80% confluence, the cells were 
trypsinized and frozen with DMEM + 20% fetal calf serum (FCS) + 10% dimethyl 
sulphoxide (DMSO) at one plate/vial at -80oC. 
 To make pooled keratinocyte cultures, one vial offrozen foreskin keratinocytes was 
thawed and plated in complete-keratinocyte serum free media (C-KSFM). After reaching 
80% confluency, the cells were trypsinized, counted and an equal number of cells from 
foreskins of 5 individuals vials (HFK pool 13: 602, 603, 607, 608 or HFK pool 14: 605, 
612, 613, 614, 615) were mixed and refrozen at 1.28 x 106and 1.8 x 106 cells/vial in C-
KSFM. Hypoxia was mimicked by addition of 100 µM deferoxamine mesylate (DFO, 
Sigma). 
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B. Human Microvascular Endothelial Cells (HMVECS) Culture  
 Human dermal microvascular endothelial cells (HMVECS) (Cambrex) were 
obtained at passage 7 or 8.  Cells were seeded in tissue culture flasks coated with type 1 
rat tail collagen (BD Biosciences) in complete endothelial cell growth medium -2 (EGM-
2) (Lonza) supplemented with 10% FBS (Hyclone) and 1% antibiotic/antimicotic 
(100U/ml penicillin/streptomycin and 25 µg of amphotericin B) (Invitrogen) for passage.  
Cells were collected for passage with trypsin (Invitrogen), the trypsin was neutralized 
with EBM-2 and cells were centrifuged at 500 x g for 5 minutes. Cells were resuspended 
in 5 ml EBM-2 and 20 µl was used to count live cells by trypan blue exclusion on a 
hemo-cytometer. 3-5 x 105 live cells were seeded in 75 cm2 flasks pre-coated with type 1 
rat tail collagen for passage. 
 
II. Generation of Mutants 
A. Generation of HPV 16E6E7 
 HPV 16E6E7 was generated by cloning into the BamHI and EcoRI sites of the 
pLXSN vector. Oligonucleotides EcoRI (forward CCGGAATTCACCGGTTAGTA 
TAAAAGC and BamHI (reverse CGCGGATCCGGATCAGCCATGGTAGATTATGG) 
was used to amplify the E6E7 cassette. PCR was performed as follows: 35 cycles using 
the following conditions: denatured for 30 seconds at 95oC, annealed for 30 seconds at 
60oC and elongated 7 minutes at 72oC. The PCR product was then separated on a 1% 
agarose gel and the band was excised and purified using PCR Purifican Kit (Qiagen). 2 µl 
of E6E7 were digested with 0.5 µl of BamHI (10U/µl) and EcoRI (10U/µl)(Invitrogen) 
for 1 hour at 37oC and analyzed by DNA gel electrophoresis. Digestion with BamHI and 
EcoRI allowed for positive identification due to BamHI and EcoRI sites outside of the 
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E6E7 cassette. T4 DNA ligase was used to ligate the DNA with the pLXSN vector. 
Although the HPV E6E7 cassette is immediately downstream of the p97 promoter, E6E7 
transcription was directed from the Moloney murine leukemia virus promoter-enhancer 
sequences (MMLV). The vector also contained a gene conferring neomycin resistance 
(137), which was transcribed from the simian virus 40 (SV40) promoter. Three mls of 
NZB media containing amplicillin were inoculated with a single colony and incubated at 
37oC for >16 hours with shaking (225-250 rpm). The Qiagen Mini prep kit (Qiagen, 
Valencia, CA) was used according to manufacturer’s instructions to isolate plasmid 
DNA. After the sequence was confirmed by the DNA Sequencing Core Facility 
(Indianapolis, IN), positive clones were inoculated into 250 ml of NZB media containing 
ampicillin (0.1 g/L) for >16 hours at 37oC. The Qiagen Maxi kit was used according to 
manufacturer’s instructions to extract and purify plasmid DNA on a larger scale. The 
plasmid DNA was then subcloned back into a clean pLXSN vector by digestion with 
restriction enzymes BamHI (10U/µl, Invitrogen) and EcoRI (10 U/µl, Invitrogen), 
transformed into competent cells, purified by Qiagen Maxi kit and the desired product 
confirmed again by sequencing the DNA Core Sequencing facility. 
 
B. Generation of HPV 16E6TTLE7 and HPV 16E6E7TTL 
 HPV 16 E6 and E7 mutants, HPV 16E6TTLE7 and HPV 16E6E7TTL, were 
generated using the Quick-Change Site-Directed Mutagenesis kit (#200521, Stratagene) 
according to manufacturers instructions. Oligonucleotides HPV 16E6TTLE7 (forward 
GTATATAGAGATGGGAATCCTGAGTTAACTGAATATGCTGTATGTG; reverse 
CACATACAGCATATTCAGTTAACTCAGGATTCCCATCTCTATATAC); HPV 
16E6E7TTL (forward CCGGACAGAGCCTTAGTTAACTAACATT 
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ACAATATTGTAACC; reverse GGTTACAATATTGTAATGTTAGTTAACTAA 
GGCTCTGTCCGG) were designed based on the published sequence (118) and 
purchased from Invitrogen Custom Primers. The oligonucleotides (125 ng) were 
denatured for 50 seconds at 95oC, annealed for 50 seconds at 60oC and elongated for 7 
minutes at 68oC. One microliter of Dpn I (10 U/µl) restriction enzyme was used to digest 
parental methylated and hemimethylated DNA for 1 hr at 37oC. Forty-five microliter of 
XL10-Gold ultracompetent Escherichia coli (#200314, Stratagene) were incubated with 1 
µl of the Dpn I- treated DNA on ice for 30 minutes. The transformation mixture was then 
heated for 30 seconds in 42oC water bath and then placed on ice for 2 minutes. Then 500 
µl of preheated (42oC) NZY+ broth (supplemented with 1 M MgMCL2, 1M MgSO4, and 
20 ml of 20% glucose) was added to each tube and incubated at 37oC for 1 hour with 
shaking (225-250 rpm). Two-hundred and fifty microliter of each transformation mixture 
was plated onto individual NZB agar + (100 µg/ml, Sigma) amplicillin plates and placed 
upside down in a 37oC incubator for >16 hours. Three mls of NZB media containing 
amplicillin was inoculated with a single colony and incubated at 37oC for >16 hours with 
shaking (225-250 rpm). The Qiagen Mini prep kit (Qiagen, Valencia, CA) was used 
according to manufacturer’s instructions to isolate plasmid DNA. Two microliter of 
L(16E6TTLE7)SN and L(16E6E7TTL)SN were digested with 0.5 µl of Hpa I (5 U/µl, 
Invitrogen) for 1 hour at 37oC and analyzed by DNA gel electrophoresis. Digestion with 
Hpa I allowed for positive selection due to Hpa I site within the TTL. After the 
appropriate sequence was confirmed by the DNA Sequencing Core Facility (Indianapolis, 
IN), positive clones were inoculated in 250 ml of NZB media containing ampicillin (0.1 
g/L) for >16 hours at 37oC. The Qiagen Maxi kit was used according to manufacturer’s 
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instructions to extract and purify plasmid DNA on a larger scale. The plasmid DNA was 
then subcloned back into a clean pLXSN vector by digestion with restriction enzymes 
BamHI (10 U/µl, Invitrogen) and EcoRI (10 U/µl, Invitrogen), transformed into 
competent cells, purified by Qiagen Maxi kit and confirmed again by the DNA Core 
Sequencing facility. 
 
C. Generation of HPV 16E6E7C24G 
 
HPV 16E6E7C24G Rb-binding deficient mutant was generated using the Quick-
Change Site-Directed Mutagenesis kit (#200521, Stratagene) according to manufacturers 
instructions. Oligonucleotides HPV 16E6E7C24G (forward CAGAGACAACTGA 
TCTCTACGGTTATGAGCAATTAAATGAC; reverse GTCATTTAATTGCTCATA 
ACCGTAGAGATCAGTTGTCTCTG) were purchased from Invitrogen Custom Primers 
based on the published sequence (60). The oligonucleotides (125 ng) were denatured for 
50 seconds at 95oC, annealed for 50 seconds at 60oC and elongated for 7 minutes at 68oC. 
One microliter of Dpn I (10 U/µl) restriction enzyme was used to digest parental 
methylated and hemimethylated DNA for 1hr at 37oC. Forty-five microliter of XL10-
Gold ultracompetent Escherichia coli (#200314, Stratagene) were incubated with 1 µl of 
the Dpn I- treated DNA on ice for 30 minutes. The transformation mixture was then 
heated for 30 seconds in at 42oC water bath and then placed on ice for 2 minutes. Then 
500 µl of preheated (42oC) NZY+ broth (supplemented with 1 M MgMCL2, 1M MgSO4, 
and 20 ml of 20% glucose) was added to each tube and incubated at 37oC for 1 hour with 
shaking (225-250 rpm). Two-hundred and fifty microliter of each transformation mixture 
was plated onto individual NZB agar + (25 mg/4 µl, Sigma) amplicillin plates and placed 
upside down in a 37oC for >16 hours. Three mls of NZB media containing amplicillin 
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was inoculated with a single colony and incubated at 37oC for >16 hours with shaking 
(225-250 rpm).  The Qiagen Mini prep kit (Qiagen, Valencia, CA) was used according to 
manufacturer’s instructions to isolate plasmid DNA. Two microliter of HPV 
16E6E6C24G was digested with 0.5 µl of BamHI (10 U/µl, Invitrogen) and EcoRI (10 
U/µl, Invitrogen) for 1 hour at 37oC and analyzed by DNA gel electrophoresis. After the 
mutated sequence was confirmed by the DNA Sequencing Core Facility (Indianapolis, 
IN), positive clones were inoculated in 250 ml of NZB media containing ampicillin (0.1 
g/L) for >16 hours at 37oC. The Qiagen Maxi kit was used according to manufacturer’s 
instructions to extract and purify plasmid DNA on a larger scale. The plasmid DNA was 
then subcloned back into a clean pLXSN vector by digestion with restriction enzymes 
BamHI (10 U/µl, Invitrogen) and EcoRI (10 U/µl, Invitrogen), transformed into 
competent cells, purified by Qiagen Maxi kit and confirmed again by sequencing the 
DNA Core Sequencing facility (Indianapolis, IN).  
 
III. Production of Retrovirus Stocks 
One vial of SD3443 Phoenix cells obtained from the American Type Culture 
Collection (ATCC) was thawed 1:2 onto 10 cm plates in DMEM + 10% FBS for 2-3 days 
and then split 1:10. After the cells were about 70-80% confluent, media were aspirated 
and 5 ml of DMEM (Lonza) was used to rinse the cells. The cells were then incubated in 
5 ml of DMEM and chloroquine (3.2 µl/5 ml) for approximately 15 minutes at 37oC, 5% 
CO2. Four micrograms of DNA from plasmids HPV 16E6E7, HPV 16E6TTLE7, HPV 
16E6E7TTL and HPV 16E6E7C24G were added to 20 µl of plus reagent and 730 µl of 
DMEM and allowed to sit at room temperature for 15 minutes. After 15 minutes, the 
complex was added to 30 µl of Lipofectamine (Invitrogen) in 720 µl of DMEM for an 
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additional 15 minutes. One and a half ml of the complex were added to each plate and 
incubated for at 37oC, 5% CO2. After 3.5 hours, 6.5 ml of DMEM + 20% FBS were 
added and incubated overnight at 37oC, 5% CO2. Within 24 hours, media were aspirated 
and 5 mls of complete DMEM (10% FBS + gentamicin) was added. The following day 
the retrovirus was harvested and frozen in 5 ml aliquots at -80oC. Another 5 mls of 
complete DMEM was added to each plate and then harvested the next day. The 
retroviruses were stored in 5 mls aliquots at -80oC until further use.   
 
A. Titering Retrovirus 
 
Retroviral titers were obtained by seeding 0.4 x 106 NIH 3T3 fibroblasts (ATCC) 
onto 6 cm tissue culture plates in 4 ml of DMEM + 10% calf serum (CS). The next day 
the cells were fluid changed with 2 ml of DMEM + 10% CS, 8 µg/ml polybrene (3 
mg/ml) and 20 µl of diluted retrovirus (1 x 10-2, 1 x 10-3, 1 x 10-4, 1 x 10-5). After 3 hours, 
6 ml of DMEM + 10% FBS were used to dilute the polybrene to 2 µg/ml. After two days, 
1 mg/ml G418 (50mg/ml, Sigma) selection media were added and the cells were fluid 
changed every 3 days with selection media until colonies were visible. The media were 
aspirated from the plates and the colonies were fixed and stained with Diff-quick kit 
(Invitrogen). The plates were then rinsed with distilled water and allowed to dry 
overnight. The following formula was used to calculate the viral titer. 
 
Infected virus/ml= number of colonies 
                                Virus volume (ml) x dilution factor 
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IV. Infection of pooled Human Foreskin Keratinocytes 
One vial of pooled human foreskin keratinocytes (HFKs) was thawed, plated in 
complete-serum free keratinocyte media (C-KSFM) (Invitrogen) supplemented with 
epidermal growth factor (71) and bovine pituitary extract (BPE) (Invitrogen) and grown 
to about 40% confluence. The cells were infected with 5 ml of parental virus LXSN, 
recombinant retrovirus HPV 16E6E7, HPV 16E6TTLE7, HPV 16E6E7TTL, HPV 
16E6E7C24G or HPV 6 E7 and 8 µg/ml polybrene as previously described (23, 177).  
Mock infected cells were generated by incubating HFKs with 5 ml of DMEM + 10% 
FCS and 8 µg/ml polybrene. After 6 hours the culture media was aspirated, fresh C-
KSFM was added and incubation continued for 48 hours. The cells were then split 1:4 
onto 10-cm dishes (passage 1). After selection, the antibiotic resistant cells were 
expanded in CKSFM for 2-3 days and used for further experiments as described in the 
next section.  
V.  Protein Analysis 
A.  Secreted Proteins VEGF and IL-8 
Following selection, retrovirally-transduced HFKs were transferred 1:4 onto 
mitomycin- C (4 µg/ml in ddH2O, Sigma) treated J2-3T3 fibroblasts and grown in 
complete E media until 80% confluence (passage 2). At passage 3, 2.5x106cells were 
plated in E media in 10 cm plates with 2x105 feeder cells for 24 hours. Serum-free 
conditioned media (CM) was generated by rinsing the cells three times with 4 ml of basal 
media (BM) (3 parts DMEM/1 part Ham’s F-12 with 100 U/ml of penicillin and 100 
µg/ml of streptomycin), incubating the cells for 4 hours in BM, replacing this media with 
8 ml of the same media and harvesting CM 24 hours later. Typically, 5 ml of 
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unconcentrated CM was frozen at -80oC in 1 ml aliquots and used for ELISA. For 
functional assays, CM was concentrated 30x using 15 ml Amicon Ultracel (Millipore) 
centrifugal filter devices (10000 MWCO) at 4oC for 45 minutes at 3000 rpms. Protease 
inhibitor cocktail (Sigma) and phosphatase inhibitors (20 µM Na3VO4 and 100 mM NaF, 
Sigma) were added prior to freezing at -80oC. Protein concentrations were determined 
using the Bio-Rad DC protein assay kit.Concentrated CM was frozen at -80oC in 1 ml 
aliquots and used for migration assays.  
 
B.  Intracellular Proteins: p53, pRb, HIF-1α , HIF-2α , GAPDH, Tubulin and p130 
 
In parallel with harvesting conditioned media, whole-cell lysates of the 
retrovirally-transduced HFKs were obtained by incubating two minutes on ice with 600 
µl of 1x lysis buffer [20 mM Tris, pH 6.8, 1% sodium dodecyl sulfate (SDS), 1 mM 
ethylenediamine tetraacetic acid (EDTA)] plus protease and phosphatase inhibitor 
cocktail (20 µM Na3VO4 and 100 mM NaF, Sigma) per 10 cm plate after rinsing the plate 
with PBS three times. Each cell lysate was harvested by scraping the plates; the lysate 
was placed in1.5 ml eppendorf tubes. The recovered lysate was boiled for 5 minutes to 
denature proteins and then centrifuged for 15 minutes at 4oC at 13,000 rpm to pellet any 
cellular debris. Lysate was placed into a new eppendorf tube and frozen at -80oC in 200 
µl aliquots. Protein concentrations were determined using the Bio-Rad DC protein assay 
kit. 
 
C. Western Blot Analysis 
Proteins (50 µg) were separated on 8% or 10% sodium dodecyl sulfate (SDS) 
polyacrylamide gels. The gels were run at 130 V for 1-2 hours and then removed and 
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proteins were transferred to a nitrocellulose membrane (0.45 µm, BioRad) at 100 V for 1 
hour. Following transfer, the membrane was stained with Ponceau red (BioRad), rinsed 
with 5% acetic acid (Fisher) and photographed (HP Photosmart Premier). The membrane 
was blocked in 1x Tris-buffered saline 0.1% Tween-20 (TBS-t) supplemented with 5% 
nonfat dry milk as previously described (23, 177). 
Primary antibodies were diluted in TBS-t supplemented with 5% nonfat dry milk 
used at the following dilutions as previously described (23, 177): 1:1000 for 1 hr at room 
temperature, p53 (DO-1 Sc-126, Santa Cruz), pRB (554136, BD Pharminogen); 1:500, 
HIF-1α (610958, BD Pharminogen), HIF-2α (NB100-132, Novus Biologicals); 1:1000 
overnight at 4oC, Rb2 (p130) (610262, BD Bioscience); and loading controls 1:30000 for 
1 hr at room temperature, GAPDH (MAB 374, Chemicon) and 1:5000 for 1 hr at room 
temperature, Tubulin (Sigma). Secondary goat anti-mouse horseradish peroxidase (HRP) 
(BioRad) was diluted 1:5000 into TBS-t for 1 hr at room temperature. The Pierce ECL 
Western Blotting substrate (Thermo Scientific) protein detection system was used to 
visualize proteins. Densitometry was performed using Quality One software (BioRad). 
 
VI. Neutralization Studies 
 Concentrated CM (500 µg) from LXSN and L(16E6E7)SN was incubated with 10 
µg of mouse monoclonal neutralizing antibodies (Abs) directed against IL-8 (R&D 
Systems, MAB208), VEGF (R&D Systems, MAB 293), or isotype controls (IgG1 for IL-8 
(R&D Systems, MAB002) or IgG2B for VEGF (R&D Systems, MAB 004) and rotated for 
2 hours at 4oC. Twenty µl of 50% vol/vol of protein G sepharose beads (Roche, 
#11719416001) in 1 x phosphate buffered saline (PBS) was added and rotated for 2 
hours. The beads were then centrifuged at 4,000 rpm for 30 seconds and the supernatants 
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were collected into microfuge tubes. The protein concentration of the supernatants was 
determined using the Bio-Rad DC protein assay kit. The supernatants were then frozen at 
-80oC and used for ELISA and migration assays. 
 
VII.  Enzyme-Linked Immunosorbent Assay (ELISA) 
A. VEGF Analysis 
VEGF165 secretion was detected in unconcentrated cell supernatants using the 
Quantikine Human VEGF ELISA kit (R&D systems). Monoclonal antibodies specific for 
VEGF were pre-coated onto the microplates. To generate standards, human VEGF was 
diluted with Calibrator Diluent RD5K (supplied by the manufacturer). The undiluted 
standard served as the highest standard (1000 pg/ml) and two-fold dilutions were made 
until the lowest concentration (15.6 pg/ml) was obtained. The calibrator diluent served as 
the zero standard (0 pg/ml). Fifty microliters of diluent RD1W, a buffered protein base 
supplied by the manufacturer, was added to each well and 200 µl of standards and 
samples were then added. Each sample was assayed in triplicate. The plate was incubated 
at room temperature for 2 hours and then washed three times with wash buffer. Two 
hundred microliters of VEGF conjugate antibody, a polyclonal antibody against VEGF 
conjugated to HRP, was added for 2 hours at room temperature. The plate was washed 
three times and 200 µl of the substrate solution was added to each well for 20 minutes at 
room temperature with protection from light. Adding 50 µl of 2N sulfuric acid stopped 
the reaction. The optical density (OD) of each well was measured within 30 minutes, 
using the Spectra Max Plus (Molecular Devices) with the plate reader set to 450 nm. 
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B. IL-8 Analysis 
IL-8 secretion was detected in unconcentrated cell supernatants using the 
Quantikine Human CXCL8/IL-8 ELISA kit (R&D systems). Monoclonal antibodies 
specific for IL-8 were pre-coated onto the microplates. To generate standards (2000 
pg/ml to 31.2 pg/ml), two-fold dilutions of human IL-8 were made in Calibrator Diluent 
RD5P supplied by the manufacturer. The calibrator diluent served as the zero standard (0 
pg/ml). One hundred microliters of diluent RD1-85, a buffered protein base supplied by 
the manufacturer, was added to each well and 50 µl of standards and samples were then 
added. Each sample was assayed in triplicate. The plate was incubated at room 
temperature 2 hours and then washed four times with wash buffer. One hundred 
microliters of IL-8 conjugate antibody, a polyclonal antibody against IL-8 conjugated to 
HRP, was added for 1 hour at room temperature. The plate was washed four times and 
200 µl of the substrate solution was added to each well for 30 minutes at room 
temperature protected from light. The reaction was stopped and results determined as for 
VEGF. 
 
VIII. RNA Analysis 
Total RNA was isolated from the retrovirally-transduced keratinocytes using 1 ml 
Tri Reagent (Molecular Research Center) according to the manufacturer’s instructions.  
During isolation, contaminating DNA was removed by digestion using the RNase-free 
DNase kit according to manufacturer’s instructions (Qiagen). After isolation, the quality 
of the RNA was determined by electrophoresis through a 2% tris-acetate-ethylenediamine 
tetraacetic acid [TAE] agarose gel containing ethidium bromide (EtBr). The products 
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were visualized by Quality-One software (BioRad). TheRNA was quantitated by 
Beckman Coulter (Schaumburg, IL). 
 
A.  Semi-quantitative limiting cycleRT-PCR 
 Semi-quantitative reverse transcriptase polychain reaction (RT-PCR) was used to 
amplify 1 µg of RNA from retrovirally-transduced HFKs as previously described (23, 
177). Amplification of the cDNA was stopped at 22 cycles for GAPDH, 26 cycles for 
VEGF and 28 cycles for IL-8. The products were visualized by EtBr staining and 
analyzed with Quality-One software (Bio-Rad). All primers were designed by Invitrogen 
Custom Primers. Reverse transcription was done for 30 minutes at 50oC followed by 2 
minutes at 94oC. Denaturation was done for 15 seconds at 94oC, annealing for 30 seconds 
and elongation for 1 minute at 72oC. The following primers (10 µM) and annealing 
temperature were used as previously described (23, 177)- GAPDH forward 
GAAGGTGAAGGTCGGAGTCA; reverse GAAGATGGGATGGGATTTC annealing 
temperature 55oC; VEGF forward CGAAGTGGTGAAGTTCATGGTG;  
reverse TTCTGTATCAGTCTTTCCTGGTGAG annealing temperature 55oC; IL-8 
forward ACATACTCCAAACCTTTCCACCC; reverse CAACCCTCTGCACCCA 
GTTTTC annealing temperature 55oC.  
 
IX.  In vitro Migration Assay 
 The endothelial cell migration assay was performed as previously described (23, 
116)with minor modifications. The upper and lower chamber of the transwell inserts with 
8 µm pores (3422, Costar) were coated with 60 µl of type I rat tail collagen 50 µg/ml (BD 
Pharmingen) and incubated for no more than 90 minutes at 37oC, 5% CO2. The collagen 
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was aspirated and the transwell inserts were placed into individual wells of a 24 well 
tissue culture plate.  2 x104 human dermal microvascular endothelial cells (HMVECs) 
were suspended in 100 µl of EBM-2 (Cambrex) supplemented with 0.5% BSA and added 
to the top of each transwell. Six hundred microliters of EBM-2 supplemented with 0.5% 
BSA, VEGF (100-20, 50 ng/ml, Peprotech) or conditioned media (50 µg) from 
retrovirally-transduced HFKs was added to the lower chamber of each transwell. Cells 
were incubated for 3.5 hrs at 37oC, 5% CO2. Non-migrating cells were removed using a 
cotton swab; migrating cells were fixed with 600 µl of methanol and stained with Diff-
quick kit (Invitrogen). Six high power fields (HPFs) of cells on the bottom of the 
membrane were counted in each individual well with an inverted microscope at 20x 
magnification. Assays were performed in triplicate. Results are reported as average 
number of migrated cells + standard error of the mean (SEM). 
 
X.  Statistical Analysis 
 Student unpaired two tailed t-test (Prism GraphPad 4.0) was used for statistical 
analysis. P values less than 0.05 were regarded as significant. 
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RESULTS 
 
Chapter I.  Construction and Characterization of HPV 16E6TTLE7 and HPV 
16E6E7TTL 
A.  Construction of HPV 16E6E7 
 The HPV 16 E6E7 cassette was previously cloned into the retrovirus LXSN by the 
Galloway laboratory (66). The cloning strategy, however, did not allow manipulation of 
the cassette. Therefore, the same E6E7 cassette was amplified using primers containing 
EcoRI (forward) and BamHI (reverse) sites. BamHI and EcoRI were also used to isolate 
the E6E7 cassette from HPV16. The PCR products were then ligated into pLXSN vector 
(ATCC) (Figure 8.). Transcription of HPV genes within the vector is directed from the 
Moloney murine leukemia virus promoter enhancer sequences. The vector also contains a 
gene conferring neomycin resistance, which is transcribed from the simian virus 40 
promoter (Figure 8). HPV 16E6E7 retrovirus was generated according to previously 
described procedures in Materials and Methods. Briefly, plasmid DNA was transfected 
into SD3443 Phoenix packaging cell line using Liptofectamine. The virus produced was 
used to infect pooled human foreskin keratinocytes (HFKs). 
 
B. Validation of HPV 16E6E7 
Expression of HPV 16 E6 results in degradation of p53, while expression of HPV 
16 E7 results in degradation of Rb (17, 147). Thus to confirm that E6 and E7 proteins  
 
 
39 
 
Figure 8. Schematic of DNA encapsidated in the retrovirus used to transduce 
human foreskin keratinocytes with HPV 16 E6 and E7 (the HPV 16 E6E7 cassette).   
Recombinant retrovirus containing the coding sequence for HPV 16E6E7 under 
the control of the viral Long Terminal Repeat (80). The neomycin resistant gene was 
expressed under the control of the SV40 promoter, allowing selection of infected cells 
with G418. Numbers under the HPV 16E6E7 cassette indicate the nt numbers at the 
beginning and end of the cloned fragment. The ATG for E6 is at nt 83; for E7 is at nt 562.  
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were functioning as expected, using the Galloway virus HPV 16E6E7as the control, 
western blot analysis was performed on whole cell lysates to detect levels of p53 and Rb.  
There was at least a 2-fold decrease in p53 expression in cells expressing HPV 16E6E7 
and HPV 16E6E7 relative to LXSN transduced HFKs (Figure 9). The levels of Rb 
protein in cells infected with HPV 16E6E7 was not decreased relative to LXSN 
transduced HFKs (Figure10). However, this result is consistent with that of the Galloway 
laboratory (Figure 10). These results demonstrate that the new retrovirus HPV 16E6E7 
was performing identically to that of the Galloway laboratory. Rb may not be decreased 
because the mRNA is mostly unspliced, favoring increased expression of E6, which 
stabilize Rb (see Discussion). 
 
C.  Transfected HPV 16 genome in pooled human foreskin keratinocytes expresses 
more spliced message than retrovirally transduced HPV 16 E6 and E7.  
 As discussed in the Introduction, splicing is important for the regulation of E6 and 
E7 gene expression in the intact HPV 16 genome (38, 151)(156)(168). In HPV16, E6 and 
E7 are transcribed as a single bicistronic transcript using a common promoter, p97. 
Within the E6 ORF there is one 5’ splice site (ss) at nucleotide (nt) 226 and two 
alternative 3’ ss at nt 409 and 526 in the virus genome. Splicing of nt 226 to 409 creates 
E6*I, and splicing to nt 526 produces E6*II. Studies from various laboratories have 
demonstrated that the majority of the transcripts in cancer tissues and cervical cancer cell 
lines are E6*I. (156)(24)(152). In contrast, splicing is inefficient in the retrovirus, HPV 
16E6E7, and, as a result, full-length unspliced message is made (96). To confirm that 
splicing is inefficient in cells infected with the retrovirus HPV 16E6E7, semi-quantitative  
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Figure 9. The effect of expressing HPV 16E6E7, HPV 16E6TTLE7 or HPV 
16E6E7TTL in pooled HFKs on the steady state level of p53.  
 Thirty microgram of protein in whole cell lysate from pooled HFKs transduced 
with LXSN, HPV 16E6E7, HPV 16E6E7, HPV 16E6TTLE7 or HPV 16E6E7TTL 
expressing cells, were separated on a 10% gel. Proteins were transferred to nitrocellulose 
membrane and probed with antibody to p53 and GAPDH. The results shown are 
representative of three independent experiments. GAPDH serves as a loading control. 
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Figure 10. The effect of expressing HPV 16E6E7, HPV 16E6TTLE7 or HPV 
16E6E7TTL in pooled HFKs on the steady state level of Rb.  
 Thirty microgram of protein in whole cell lysate from pooled HFKs transduced 
with LXSN, HPV 16E6E7, HPV 16E6E7, HPV 16E6TTLE7 or HPV 16E6E7TTL 
expressing cells, were separated on an 8% gel. Proteins were transferred to nitrocellulose 
membrane and probed with antibody to Rb and GAPDH. The results shown are 
representative of three independent experiments. GAPDH serves as a loading control. 
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RT-PCR was performed on RNA isolated from HFKs expressing LXSN, HPV 16E6E7 
and HPV 16E6E7. Primers 106 and 562 were used to amplify E6 and E7. As anticipated, 
unspliced message was expressed in HFKs retrovirally transduced with HPV 16E6E7 and 
HPV 16E6E7, relative to HPV 16, which expressed more spliced message as shown in 
Figure 11. 
 
D.  Transduced HPV 16 E6TTLE7 in pooled human foreskin keratinocytes 
expresses more spliced message than HPV 16 E6 and E7 or HPV 16 E6E7TTL.  
To determine the individual contributions that E6 and E7 play in inducing 
angiogenesis, translational termination linkers (TTLs) were placed within the open 
reading frames of either the E6 coding sequence at nt 280 or the E7 coding sequence at nt 
711 and spliced versus unspliced message was examined. Semi-quantitative RT-PCR was 
performed on RNA isolated from HFKs expressing LXSN, HPV 16E6E7, HPV 
16E6TTLE7 or HPV 16E6E7TTL. Primers 106 and 562 were used to amplify mRNA 
across the nt 226 through nt 409 splice junction. HFKs retrovirally transduced with HPV 
16E6E7 and HPV 16E6E7TTL expressed predominantly unspliced message. 
Surprisingly, more spliced message was expressed in HFKs retrovirally transduced with 
HPV 16E6TTLE7 compared to HPV 16E6E7 or HPV 16E6E7TTL (Figure 11). In 
addition, placement of the TTL at nt 280 within E6 creates a premature stop codon 
therefore providing more E7 RNA templates and translation of E7.  
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Figure 11. HPV 16E6TTLE7 produces more spliced message relative to HPV 
16E6E7 or HPV 16E6E7TTL. Semi-quantitative RT-PCR was performed using 0.5 µg 
of RNA isolated from HFKs expressing LXSN, HPV 16E6E7, HPV 16E6TTLE7 or  
HPV 16E6E7TTL. Primers 106 and 562 were used to amplify E6 and E7.  
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E.  Expression of HPV16E6TTLE7 in pooled human foreskin keratinocytes does not 
decrease the tumor suppressor p53 relative to LXSN transduced HFKs.  
Expression of HPV 16 E6 results in degradation of p53, (147). If disruption of the 
E6 gene is successful, p53 will not be degraded. Thus, to confirm that insertion of a TTL 
results in loss of function of E6, the expression level of p53, a surrogate marker for E6 
protein, was determined by Western blot analysis. As expected, relative to LXSN, p53 
protein was not decreased in cells infected with HPV 16E6TTLE7 (Figure 9). In fact, the 
levels of p53 were increased in the presence of E7 relative to LXSN. This is consistent 
with previously published data which indicate that expression of HPV 16 E7, in the 
absence of E6, increases the steady state level of p53 protein, (34, 35)(150). These results 
demonstrate that the mutant is indeed null for E6. 
 
F.  Expression of human papillomavirus HPV16E6E7TTL in pooled human foreskin 
keratinocytes does not decrease the tumor suppressor, Rb, relative to LXSN 
transduced HFKs.  
Expression of HPV 16 E7 results in degradation of Rb, (17). Thus, to confirm that 
insertion of a TTL results in loss of function of E7, the level of Rb, a surrogate marker for 
E7 protein, was monitored by Western blot analysis. If disruption of the E7 gene is 
successful, Rb will not be degraded. As expected, relative to LXSN, Rb protein 
expression was not decreased in cells infected with HPV 16E6E7TTL (Figure 10). In 
fact, the levels of Rb were increased in the presence of E6 relative to LXSN. These 
results demonstrate that the mutant is indeed null for E7. This is also consistent with 
published data which indicate that expression of HPV 16 E6 in the absence of E7 
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increases the steady state level of Rb protein (111). Taken together the data in (Figures 9 
and 10) indicate that the E6 and E7 mutants are functioning as expected. 
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Chapter II. Establish whether HPV 16 E6 and/or E7 is required for increased 
expression of VEGF and/or IL-8 and to induce an angiogenic response. 
The results of the previous chapter indicate that HPV 16E6TTLE7 and HPV 
16E6E7TTL are loss of function with respect to targeting p53 or Rb, respectively, for 
degradation. Additionally, HPV 16E6TTLE7 increased the steady state levels of p53 and 
HPV 16E6E7TTL increased the steady state levels of Rb. In this chapter the hypothesis 
that increased expression of VEGF and IL-8 requires expression of E6 and/or E7 and 
whether E6 and/or E7 is sufficient for an angiogenic response will be tested. To examine 
the ability E6 and/ or E7 loss of function mutants to affect expression of the angiogenic 
inducers VEGF and IL-8, ELISAs were used. To characterize the ability of conditioned 
media from HFKs expressing HPV 16E6TTLE7 and or HPV 16E6E7TTL to alter 
endothelial cell behavior, endothelial cell migration assays were used. 
 
A. Expression of HPV 16 E6TTLE7 and HPV 16 E6E7TTL in pooled human 
foreskin keratinocytes significantly upregulates IL-8 secretion.  
To determine whether E6 and E7 each contributes to the increase of secreted IL-8, 
HFKs were transduced with control retrovirus LXSN, HPV 16E6E7, HPV 16E6TTLE7 
or HPV 16E6E7TTL. Conditioned media from the cells expressing HPV 16E6E7TTL 
had a 2.9 +/- 0.3 fold increase in the level of secreted IL-8 relatively to LXSN (p<0.001). 
Cells expressing HPV 16E6TTLE7, however, had an 11.7 +/- 0.6 fold increase in the 
level of secreted IL-8 relative to LXSN (p<0.0001) (Figure 12). 
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Figure 12. Levels of IL-8 in conditioned media were increased in cells expressing 
either E6 or E7.  
 The quantity of IL-8 was determined by ELISA and normalized to total protein in 
the conditioned media. The data represent mean ± SEM and are representative of three 
experiments each conducted in triplicate. p< 0.0001for LXSN vs 16E6E7 and LXSN vs 
HPV 16E6TTLE7; p< 0.001 for LXSN vs HPV 16E6E7TTL; p< 0.001 for HPV 16E6E7 
vs HPV 16E6TTLE7 and p< 0.0005 for HPV 16E6E7 vs HPV 16E6E7TTL.  
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Conditioned media from the cells expressing HPV 16E6TTLE7 also significantly 
enhanced the expression of IL-8 relatively to HPV 16E6E7 (p <0.0001). In contrast, 
although, relative to LXSN, the level of IL-8 was significantly increased in HPV 
16E6E7TTL-expressing cells, the level of increase was much less than that seen with 
HPV 16E6E7. Therefore, E7 seems to play a greater role in upregulating IL-8 than E6. 
 
B. Expression of HPV 16E6TTLE7 and HPV 16E6E7TTL in pooled human foreskin 
keratinocytes significantly upregulates VEGF secretion.  
To determine whether E6 and E7 each contributes to the increase of secreted VEGF 
seen when HPV 16E6E7 are expressed together in HFKs (23, 177), HFKs were 
transduced with control retrovirus LXSN, HPV16E6E7, HPV 16E6TTLE7 or HPV 
16E6E7TTL. Conditioned media from the cells expressing HPV 16E6TTLE7 or HPV 
16E6E7TTL caused an 4.8 +/- 0.3 fold and 2 +/- 0.1 fold (p< 0.0001 and p< 0.001) 
increase in the expression of VEGF relatively to LXSN (Figure 13). Conditioned media 
from the cells expressing HPV 16E6TTLE7 also caused a 3.3 +/- 0.04 fold (p< 0.0001) 
increase in expression of VEGF relatively to HPV 16E6E7. In contrast, although, relative 
to LXSN, the level of VEGF was significantly increased in HPV16E6E7TTL-expressing 
cells, the level of increase was only slightly greater than that seen with HPV 16E6E7. 
Therefore, E7 seems to play a greater role in upregulating VEGF than E6. 
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Figure 13. Levels of VEGF in conditioned media were increased in cells expressing 
either E6 or E7.  
 The quantity of VEGF was determined and normalized to total protein in the 
conditioned media. The data represent mean ± SEM and are representative of three 
experiments each conducted in triplicate. p< 0.001 for LXSN vs HPV 16E6E7; p< 0.0001 
for LXSN vs HPV 16E6TTLE7; p< 0.001 for LXSN vs HPV 16E6E7TTL; p< 0.0001 for 
HPV 16E6E7 vs HPV 16E6TTLE7 and p< 0.001 for HPV 16E6E7 vs HPV 16E6E7TTL.  
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C. Conditioned media from pooled HFKS transduced with HPV 16E6TTLE7 or 
HPV 16E6E7TTL did not induce migration of human microvascular endothelial 
cells (HMVECs) in vitro. 
 To determine whether of E6 or E7 alone contribute to the altered endothelial cell 
behavior seen when HPV 16E6E7 are expressed together in HFKs (23, 177), migration 
assays were used. Human microvascular endothelial cells (HMVECs) were placed in the 
top of a transwell plate and concentrated media from control HFKs or HFKs expressing 
HPV gene products were placed in the bottom well and migration was monitored as 
described in Materials and Methods. Consistent with previous results, conditioned media 
from HPV 16E6E7-expressing cells increased the migration of HMVECs (Figure 14). In 
contrast, concentrated conditioned media from retrovirally transduced cells expressing 
HPV 16E6TTLE7 or HPV 16E6E7TTL did not induce migration of HMVECs relative to 
LXSN (Figure 14). Consistent with these observations, the level of migration of 
endothelial cells seen in the presence of conditioned media from HPV 16E6E7 expressing 
cells was statistically different from that seen with either HPV 16E6TTLE7 or HPV 
16E6E7TTL (0.8 +/- .12 fold and 0.9 +/- 0.13 fold respectively). These results indicate 
that both E6 and E7 are required to alter endothelial cell behavior. 
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Figure 14. Conditioned media from pooled HFKs transduced with either E6 or E7 
did not induce migration of HMVECs in vitro.  
 HMVECs were plated on a collagen-coated transwell membranes. Conditioned 
media from HFKs retroviral transduced with LXSN, HPV 16E6E7, HPV 16E6TTLE7 or 
HPV 16E6E7TTL were added to the bottom chamber. After 3 hrs, 6 high power fields 
(HPF) of cells on the bottom were counted. The data represent mean number of migrated 
cells per HPF± SEM and are representative of three experiments each conducted in 
triplicate. p< 0.005 for LXSN vs HPV16E6E7 and p< 0.02 for HPV 16E6E7 vs HPV 
16E6TTLE7 or HPV 16E6E7TTL.  
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Chapter III.   
 
A. HPV 16 E7 enhancement of VEGF is independent of HIF-1α  and HIF-2α  
expression under normoxic conditions. 
 Angiogenesis is induced in response to hypoxia. The cellular response to hypoxia is 
regulated by HIF-1α. As stated previously in the Introduction, HIF-1α is regulated by 
oxygen (10, 18).  In normoxia, constitutively expressed cytosolic HIF-1α subunits are 
hydroxylated on two proline residues and targeted for degradation by their interaction 
with the VHL proteasomal pathway (23). In hypoxia, VHL-mediated degradation of HIF-
1α is inhibited, HIF-1α is stabilized and translocates to the nucleus where it activates 
HIF-1 target genes (42, 179).  
 VEGF, a HIF-1 target gene, is an important angiogenic inducer. Our previous 
publication has shown that HPV 16E6E7 is capable of enhancing the expression of 
VEGF in HFKs under normoxic conditions (177). However, whether HIF-1α activation 
is responsible for this increased expression was unknown. A precedent for this possibility 
was provided in a publication by Kondo, et al. 2006, which showed that Epstein-Barr 
Virus (EBV) latent membrane protein-1 (LMP1) induces stabilization of Siah1, a 
ubiquitin ligase, which, in turn destabilizes the prolyl hydroxylases, thereby stabilizing 
HIF-1α under normoxic conditions (92). 
  To determine whether expression of HPV 16E6E7 had any influence on HIF-1α 
activation in normoxia and hypoxia, we first examined whether HIF-1α could be induced 
in hypoxia in the presence of HPV 16E6E7. We used the hypoxic mimicking drug, 
deferoxamine mesylate (DFO), which has previously been shown to enhance the levels of  
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Figure 15. Enhanced induction of HIF-1α  in HFKs expressing HPV 16E6E7 only in 
the presence of DFO.   
 HFKs transduced with HPV 16E6E7 or LXSN were incubated in the presence of 
100 µm DFO for 12 hrs. Fifty micrograms of whole cell lysate were separated on an 8% 
SDS polyacrylamide gel. Proteins were transferred to a nitrocellulose membrane and 
probed with antibodies to HIF-1α and Tubulin. The results are representative of three 
experiments. Tubulin serves as a loading control. 
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HIF-1α (2) as a positive control. As seen in Figure 15, treatment with DFO for 12 hrs  
induced HIF-1α in control retrovirus, LXSN or HPV 16E6E7 transduced HFKs. 
Although there was induction of HIF-1α in the presence of LXSN there was a greater 
increase in the presence of HPV 16E6E7. 
 We next examined whether the HPV 16E6E7, HPV 16E6TTLE7 or HPV 
16E6TTLE7 expressing cells had any influence on HIF-1α in normoxic conditions. As 
seen in Figure 16, HIF-1α was not detected above background in either HPV 16E6E7, 
HPV 16E6TTLE7 or HPV 16E6E7TTL expressing cells in the absence of DFO.   
 Like HIF-1α, HIF-2α also has been shown to correlate with VEGF expression (47, 
160). We used renal carcinoma cells (786 wt), which have been previously shown to 
enhance levels of HIF-2α under hypoxic conditions, as a positive control (Figure 16). 
HIF-2α was not detected above background in either HPV 16E6E7, HPV 16E6TTLE7 or 
HPV 16E6E7TTL expressing cells in the absence of a hypoxic environment (Figure 16). 
These results indicate that the presence of HPV 16E6E7, HPV 16E6TTLE7 or HPV 
16E6E7TTL is not sufficient to induce HIF-1α and HIF-2α expression under conditions 
of normoxia. Therefore the enhanced level of VEGF seen in the presence of HPV 
16E6E7 is due to HIF-1α and HIF-2α- independent mechanisms. 
 
B. VEGF is required for the increased migration of human microvascular 
endothelial cells (HMVECs) in vitro 
 Angiogenesis involves activation of endothelial cells. IL-8 and VEGF have been 
reported to regulate angiogenesis and affect endothelial cell migration and proliferation 
(70, 102, 128, 142). However, the direct role of IL-8 and VEGF in HPV-mediated  
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Figure 16. Enhanced expression of neither HIF-1α  nor HIF-2α  was detected above 
background in HPV 16E6E7, HPV 16 E6 or HPV 16 E7 expressing cells.   
 HFKs transduced with HPV 16E6E7 or LXSN were incubated in the presence or 
absence of 100 µm DFO for 12 hrs. 786 wt renal carcinoma cells were treated with 
normoxia (N) or hypoxia (H) for 24 hrs before lysis for Western blot analysis. Fifty 
micrograms of whole cell lysate were separated on an 8% SDS polyacrlyamide gel. 
Proteins were transferred to nitrocellulose membrane and probed with antibodies to HIF-
1α, HIF-2α and GAPDH. GAPDH serves as a loading control. 
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angiogenesis remains unclear. To determine whether IL-8 and/or VEGF is required for 
increased migration of endothelial cells when such cells are exposed to conditioned 
media from HPV 16E6E7 expressing cells, neutralizing Abs directed against IL-8, VEGF 
or isotype controls (mouse IgG1 or mouse IgG2B respectively), were used to deplete 
conditioned media of IL-8 or VEGF. If IL-8 is successfully depleted and the depletion is 
specific, the level of IL-8 following incubation with antibodies to IL-8 should decrease 
but the level of VEGF should not. Similarly, if VEGF is successfully depleted and the 
depletion is specific, the level of VEGF should decrease following incubation with 
antibodies to VEGF but the level of IL-8 should not. The levels of neither IL-8 nor VEGF 
should decrease following incubation with isotype controls. ELISAs documented that IL-
8 (Figure 17) and VEGF (Figure 18) were successfully and specifically depleted from 
conditioned media expressing HPV 16E6E7.  
 Conditioned media from cells expressing HPV 16E6E7 induced migration of 
HMVECS relative to LXSN, as shown in Figures 14 and 19, consistent with the literature 
(23). As seen in Figure 19, IL-8 depleted conditioned media from cells expressing HPV 
16E6E7 retained its ability to increase migration of HMVECs when compared to IL-8 
depleted conditioned media from LXSN transduced cells. However, VEGF-depleted 
conditioned media from cells expressing HPV 16E6E7 did not induce migration of  
HMVECs when compared to VEGF-depleted conditioned media from LXSN transduced 
cells in Figure19. These results indicate that VEGF, but not IL-8, is required to increase 
endothelial cell migration in response to conditioned media from HPV 16E6E7 
expressing cells. 
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Figure 17. Specific depletion of IL-8 in conditioned media from pooled HFKs 
expressing HPV 16E6E7.  
 Conditioned media from HFKs retroviral transduced with LXSN and 16E6E7 were 
depleted of IL-8 or VEGF. The data represent mean ± SEM and are representative of 
three experiments each conducted in triplicate. p< 0.0001 for LXSN vs HPV 16E6E7; 
LXSN vs HPV 16E6E7 (isotype control IgG1); LXSN vs HPV 16E6E7 (depleted of 
VEGF) and LXSN vs 16E6E7 (isotype control IgG2B).  
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Figure 18. Specific depletion of VEGF in conditioned media from pooled HFKs 
expressing HPV 16E6E7 from pooled HFKs.   
 Conditioned media from HFKs retroviral transduced with LXSN and HPV 16E6E7 
were depleted of IL-8 or VEGF. The data represent mean ± SEM and are representative 
of three experiments conducted in triplicate. p<0.02 for LXSN vs HPV 16E6E7; p<0.001 
for LXSN vs HPV 16E6E7 (depleted of IL-8); LXSN vs HPV 16E6E7 (isotype control 
IgG1); and LXSN vs 16E6E7 (isotype control IgG2B).  
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Figure 19. VEGF, but not IL-8, is required for the increased migration of HMVECS 
in vitro.  
 Conditioned media from HFKs retroviral transduced with LXSN and 16E6E7 were 
depleted of IL-8 or VEGF. The data represent mean number of migrated cells ± SEM and 
are representative of three experiments conducted in triplicate. p< 0.0001 for LXSN vs 
16E6E7 and LXSN vs 16E6E7 (isotype control IgG2B), p< 0.002 for LXSN vs 16E6E7 
(depleted of IL-8) and LXSN vs 16E6E7 (isotype control IgG1). 
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C. HPV 16E6E7C24G retains its ability to target p130 for degradation 
 HPV 16 E7 interacts with Rb as well as its family members, p107 and p130, 
through the LXCXE motif (aa 21-26). The motif contains the core for Rb pocket binding 
(40, 119, 185). Mutations in this region, especially changes to C24, result in a substantial 
loss of affinity for Rb (9, 83, 119). Data in Figures 12 and 13indicate that expression of 
HPV 16 E7 is required for the enhanced expression of IL-8 and VEGF, equivalent to or 
greater than that seen with HPV 16E6E7. Therefore, experiments were designed to test 
the hypothesis that Rb binding and degradation is required for that enhancement.  
 To test this hypothesis, HPV 16E6E7C24G was constructed, to render E7deficient 
in binding to and targeting Rb for degradation, and was used to infect pooled HFKs. If 
the mutation is successfully engineered, the level of Rb in these infected cells should not 
be decreased relative to LXSN transduced cells. In fact, as was shown in Figure 10, 
Chapter I, the level of Rb may be increased relative to LXSN and HPV 16E6E7 due to 
the presence of E6. To confirm this, we monitored expression levels of pRb, as well as 
p53, in the retrovirally-transduced cells by Western Blot analysis. As expected, relative to 
LXSN and HPV 16E6E7, Rb protein expression was increased in cells infected with HPV 
16E6E7C24G (Figure 20). Relative to LXSN, as expected, p53 expression was decreased 
in cells infected with HPV 16E6E7C24G, similarly to the decrease seen with HPV 
16E6E7 (Figure 21). These results demonstrate that the mutant is indeed deficient for 
targeting Rb for degradation. 
 Although the C24G mutant has been reported to continue to target another Rb 
family member, p107 for degradation (60), its ability to target p130 for degradation has  
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Figure 20. The steady state level of Rb is increased in pooled HFKs expressing HPV 
16E6E7C24G relative to LXSN. 
 Fifty micrograms of whole cell lysate from pooled HFKs transduced with LXSN, 
HPV 16E6E7, HPV 16E6TTLE7, HPV 16E6E7C24G or HPV 6 E7, were separated on an 
8% SDS polyacrylamide gel. Proteins were transferred to nitrocellulose membrane and 
probed with antibodies to Rb and Tubulin. Tubulin serves as a loading control. 
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Figure 21. Expression of HPV 16E6E7C24G in pooled HFKs does not affect the 
ability of E6 to target p53 for degradation.  
 Fifty micrograms of whole cell lysate from pooled HFKs transduced with LXSN, 
HPV 16E6E7, HPV 16E6TTLE7, HPV 16E6E7C24G or HPV 6E7, were separated on an 
8% SDS polyacrylamide gel. Proteins were transferred to nitrocellulose membrane and 
probed with antibodies to p53 and Tubulin. Tubulin serves as a loading control. 
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not been reported. Therefore, the effect of HPV 16E6E7C24G on p130 expression was 
determined by Western Blot analysis. As expected, the level of p130 in cells expressing 
wt E7 (HPV 16E6E7 or HPV 16E6TTLE7) was decreased relative to LXSN (Figure 22).  
Further, even in the E7C24G mutant (HPV 16E6E7C24G), p130 was decreased in cells 
expressing HPV 16E6E7C24G relative to LXSN (Figure 22). These results demonstrate 
that HPV 16E6E7C24G, which does not destabilize Rb (Figure 22) (60), retained the 
ability to decrease the steady state level of p130. 
 
D. Rb binding and degradation is not required for the enhanced expression of IL-8 
and VEGF. 
 To determine whether degradation of Rb was required for increased expression of 
IL-8 or VEGF, conditioned media from retrovirally transduced HFKS, were analyzed by 
ELISA to quantitate the levels of secreted IL-8 and VEGF. As in Figures 12 and 13, 
expression of HPV 16E6E7 or HPV 16E6TTLE7 significantly increased the levels of 
both angiogenic inducers relative to LXSN (Figures 23 and 24). Conditioned media from 
cells expressing HPV 16E6E7C24G had a 2.2 +/- 0.10 fold increase (p< 0.0001) in the 
level of secreted IL-8 compared to retrovirus control LXSN, although not to the same 
extent as seen with conditioned media from HPV 16E6E7 and HPV 16E6TTLE7 
expressing cells (Figure 23). However, VEGF expression was increased 8.7 +/-1.6 fold 
(p< 0.0001) in cells expressing HPV 16E6E7C24G compared to retrovirus control LXSN 
and to a greater extent than conditioned media from HPV 16E6E7 or HPV 16E6E7TTL 
expressing cells (Figure 24). These preliminary data suggest that HPV 16 E7 binding to 
Rb is required for maximally enhanced IL-8 and VEGF expression. Further experiments  
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Figure 22. HPV 16E67C24G, which does not associate with Rb, is still capable of 
targeting p130 for degradation.  
 Fifty micrograms of whole cell lysate from pooled HFKs transduced with LXSN, 
HPV 16E6E7, HPV 16E6TTLE7, HPV 16E6E7C24G or HPV 6 E7, were separated on an 
8% SDS polyacrylamide gel. Proteins were transferred to nitrocellulose membrane and 
probed with antibodies to p130 and Tubulin. Tubulin serves as a loading control. 
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Figure 23. Levels of IL-8 in conditioned media were increased in cells expressing 
HPV 16E6E7C24G.  
 The quantity of IL-8 was determined and normalized to total protein in the 
conditioned media. The data represent mean ± SEM and are representative of two 
experiments each conducted in triplicate. p< 0.0001 for LXSN vs HPV 16E6E7; LXSN 
vs HPV 16E6TTLE7; LXSN vs HPV 16E6E7C24G and LXSN vs HPV 6 E7. 
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Figure 24. Levels of VEGF in conditioned media were increased in cells expressing 
HPV 16E6E7C24G.  
 The quantity of VEGF was determined and normalized to total protein in the 
conditioned media. The data represent mean ± SEM and are representative of two 
experiments each conducted in triplicate. p< 0.0001 for LXSN vs HPV 16E6E7; LXSN 
vs HPV 16E6TTLE7; LXSN vs HPV 16E6E7C24G and LXSN vs HPV 6 E7. p< 0.0003 
for  HPV 16E6E7 vs HPV 16E6E7C24G and p < 0.02 for HPV 16E6E7 vs 
HPV16E6TTLE7. 
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need to be conducted in order to validate these results. 
 
E. Low risk HPV 6 E7 also increases IL-8 and VEGF expression 
 Low-risk virus HPV 6 E7 has been shown to target Rb family member p130 for 
degradation (191). VEGF and p130 expression are inversely correlated (145). ELISAs 
were used to determine the ability of HPV 6E7 to induce VEGF and IL-8 expression. 
Conditioned media from cells expressing HPV 6E7 caused a 5.2 +/- 1.0 fold and 6.4 +/- 
0.10 fold (p< 0.0001) increase in the level of secreted VEGF and IL-8 compared to 
retrovirus control LXSN (Figures 23 and 24); comparable to the levels seen in 
conditioned media from cells transduced with HPV 16E6TTLE7. 
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DISCUSSION 
 
 The study described in this thesis were undertaken to determine the individual 
contributions of human papillomavirus type 16 E6 and E7 oncoproteins in regulating the 
angiogenic response seen in the early stages of cervical cancer. To do so, translation 
termination linkers were introduced into the coding region of E6 or E7. Human foreskin 
keratinocytes were retrovirally transduced with the mutated cassette; the ability of E7 in 
the context of the E6TTL mutation (E6TTLE7) and E6 in the context of the E7TTL 
mutation (E6E7TTL) to induce VEGF and IL-8 was analyzed. We showed that the 
expression of E6 or E7 in human foreskin keratinocytes significantly increased the 
expression of both VEGF and IL-8. E7, however, is the major contributor. We have 
shown that the effect on VEGF was independent of HIF-1α and HIF-2α. Here we have 
shown that conditioned media from either E6 or E7 expressing cells does not induce 
migration of human microvascular endothelial cells (HMVECs). In addition, 
immunological depletion experiments showed that VEGF is required for HPV 16E6 and 
E7 together to induce HMVEC migration. Data further show that the ability of HPV 16 
E7 to induce IL-8 and VEGF may be dependent upon degradation of the Rb family 
member p130.  
 
A. Transduced HPV 16E6TTLE7 in pooled human foreskin keratinocytes expresses 
more spliced message than HPV 16 E6 and E7 or HPV 16E6E7TTL. 
 As discussed in the Introduction, splicing is important for the regulation of E6 and 
E7 in the intact genome. During a natural infection, HPV 16 E6 and E7 are transcribed as 
a single bicistronic transcript (Figure 4). Splicing occurs within the E6 coding region 
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from nt 226 to nt 409 creating truncated E6*I. The majority of transcripts within cancer 
tissues and cervical cancer cell lines are E6*I (15, 38, 152, 192, 194). Translation of E7 is 
dependent upon splicing (193). Splicing depends on the distance of the splice donor from 
the promoter (96). The distance between the termination of E6 translation and the 
reinitiation of E7 translation is approximately 2 nucleotides. E6*I contains a premature 
codon immediately downstream of the splice junction creating enough space for 
termination of E6 translation and the reinitiation of E7 translation (93) therefore 
benefiting the expression of E7. Unspliced mRNA is translated into E6. 
In the context of the retrovirus, splicing is inefficient. E6 and E7 expression is 
dictated not by the P97 promoter but by the retroviral long terminal repeat (LTR).  Cells 
infected with the retrovirus undergo splicing less frequently due to the distance between 
the LTR and the splice donor at nt 226 (96).  
We have shown that more spliced message was expressed in HFKs retrovirally- 
transduced with HPV 16E6TTLE7 compared to HPV 16E6E7 or HPV 16E6E7TTL 
(Figure 12). Even without the enhanced splicing, placement of the TTL at nt 280 within 
E6 should increase E7 mRNA templates therefore favoring expression of E7. The 
splicing within this mutated sequence appears to mimic splicing seen within the natural 
infection. This is in contrast to the TTL placed at nt 711 within the E7 coding region, this 
does not affect the translation of E6. This increase in E7 mRNA template may explain 
why an even greater increase in the level of secreted VEGF and IL-8 seen in cells 
expressing HPV 16E6TTLE7 compared to HPV 16E6E7 or HPV 16E6E7TTL in Figure 
13 and 14.  
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B. Expression of HPV 16E6TTLE7 in pooled HFKs reduces the levels of Rb while 
the levels of p53 are increased relative to LXSN transduced HFKs 
 E6 and E7 target the tumor suppressors p53 and Rb, respectively, for degradation. 
In contrast, we have shown that expression of E7 in the absence of E6 (HPV 
16E6TTLE7) leads to stabilization of p53 as well as the induction of p21 (data not 
shown), which is consistent with the literature (35, 82, 150, 170). However, the 
mechanism underlying this stabilization of p53 by E7 remains unclear.  
 One possible mechanism for the increased steady state level of p53 function by E7 
is through p53 interaction between E2F and MDM2. E7 degradation of Rb liberates E2F 
from Rb and overexpression of E2F1 is known to increase both p53 and MDM2 (196). 
This result was shown to be independent of p19ARF. Seavey et al. 1999 showed that E7, 
like E2F1, could increase the levels of both p53 and MDM2 in normal diploid human 
fibroblasts lacking p19ARF(150). Therefore, E7 and E2F1 may stabilize p53 through a 
mechanism independent of p19ARF. Another possible mechanism for E7-mediated 
increase in the steady state level of p53 is that E7 interferes with the function of p300, 
which serves as a platform for the stimulation of degradation of p53 by MDM2 (63).
 We have also shown that expression of E6 in the absence of E7 leads to 
stabilization of Rb, which is consistent with the literature (111). However, the mechanism 
underlying this stabilization of Rb by E6 also remains unclear. A possible mechanism for 
E6 dependent stabilization of Rb may be through the activities of the cyclin dependent 
kinases (CDKs), which are involved in the phosphorylation of Rb (cyclin A/CDK4, 
Cyclin D/CDK6 and cyclin A/CDK2). Degradation of p53 in the presence of E6 and 
inhibition of p53-induced expression of cyclin-dependent kinase inhibitor p21 may lead 
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to increase activity of CDKs, leading to increased stability of Rb. Therefore, E6 could 
stimulate phosphorylation of Rb by enhancing levels of CDK4/6 (111). However, how E6 
stimulates levels of CDK4/6 is unknown and needs to be further explored. 
 
C. Possible Mechanism of HPV 16 E6 and HPV 16 E7 Enhancement of IL-8. 
 The Roman laboratory has previously shown that expression of HPV 16E6 and E7 
together is sufficient to cause an increase in the angiogenic inducer IL-8 (177). The 
ability of E6 and E7 alone to alter the expression of IL-8 was not investigated. 
Experiments were therefore designed to test the hypothesis that E6 or E7 alone is 
sufficient to alter the expression of IL-8. Human foreskin keratinocytes (HFKs) were 
infected with recombinant retrovirus expressing HPV 16E6TTLE7 or HPV 16E6E7TTL. 
ELISAs was used to analyze IL-8 expression. In cells expressing HPV 16E6TTLE7 or 
HPV 16E6E7TTL, the levels of secreted IL-8 were upregulated relative to control LXSN 
transduced HFKs.   
 As discussed in the Introduction, IL-8 expression is controlled at the transcriptional 
and the posttranscriptional level (72). IL-8 expression is regulated in cooperation with 
three inducible transcription factors, NFκB, AP-1 and C/EBP depending upon cell type 
and stimulus (72). Desaintes et al. showed that HPV 16 E6 is able to transactivate 
promoters containing NFκB sites (Figure 25) (36). One possible mechanism for 16 E7’s 
ability to enhance IL-8 expression is through C/EBPα. CEB/Pα is a positive regulator of 
IL-8 expression. Timchenko et al. found that C/EBPα regulates E2F/p107 and E2F/p130 
complexes (174). Specifically, C/EBPα disrupts E2F/p107 complexes, while E2F/p130 
complexes are induced (174). We propose that HPV 16 E7 ability to enhance IL-8 
expression is due to HPV 16 E7’s ability bind and target p107 and p130 for degradation  
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Figure 25. Possible Mechanism of HPV 16 E6 Enhancement of IL-8. 
   HPV 16 E6 transactivates NFκB thereby leading to the enhancement of IL-8.  
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thereby leading to the positive regulation of C/EBP and enhancing IL-8 expression 
(Figure 26). HPV 16 E7 is also able to transactivate promoters containing AP-1 sites (3). 
Perhaps HPV 16 E7’s ability to transactivate this additional site may result in the greater 
increase in IL-8 expression. 
 
D. Possible Mechanism of HPV 16 E6 and HPV 16 E7 Enhancement of VEGF 
 Previous data from the Roman laboratory has determined that expression of both E6 
and E7 are sufficient to enhance VEGF. Whether E6 or E7 alone was sufficient was 
examined. Conditioned media from cells expressing HPV 16E6E7TTL or HPV 
16E6TTLE7 increased the levels of secreted VEGF relative the control LXSN transduced 
HFKs. One possible mechanism for the ability of HPV 16 E6 to increase expression of 
VEGF is through the coactivator p300, which is important for cell cycle progression and 
differentiation. Both HIF-1α and p53 bind to distinct regions of p300 and p300 is 
required for full activity of both transactivators (4, 6, 64, 103, 157). Recent data proposed 
a competition between p53 and HIF-1α for p300 (32, 148). Negative regulation of HIF-1 
by p53 was evident as levels of wt p53 increased upon cellular stress such as prolonged 
or severe hypoxia, thereby leading to repression of HIF-1 stimulated transcription of a 
number of genes including VEGF (139) and HIF-1 destabilization (148). We propose that 
HPV 16 E6’s ability to bind and target p53 for degradation reverses this effect thereby 
allowing interaction between HIF-1α and p300 resulting in the enhanced expression of 
VEGF (Figure 27). Another mechanism by which HPV 16 E6 may increase expression of 
VEGF is through the transcriptional factor Sp-1 located on the VEGF promoter. It has 
been demonstrated that p53 complexes with SP-1 and inhibits Sp-1-mediated VEGF 
transciption under normoxic and hypoxic conditions (132). E6 has been shown to  
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Figure 26. Possible Mechanism of HPV 16 E7 Enhancement of IL-8. 
   (A) C/EBPα regulates E2F/pl07 and E2F/p130. (B) HPV 16 E7’s ability to bind  
and target p107 and p130 for degradation leads to the enhancement of IL-8. 
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Figure 27. Possible Mechanism of HPV 16 E6 Enhancement of VEGF. 
 (A) HIF-1α binds to p300 and enhances VEGF. (B) Negative regulation of HIF-1α 
by p53. (C). Degradation of p53 by HPV 16 E6 leads to the enhancement of VEGF. 
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regulate VEGF though SP-1 (108). We propose that E6 ability to bind and target p53 for 
degradation increases binding of Sp-1 to the VEGF promoter thereby increasing VEGF 
transcription (Figure 28). Further experiments could distinguish between each of these 
possible mechanisms.  
 The enhanced levels of HIF-1α in HPV positive cells were found to activate genes 
such as VEGF. VEGF is strongly induced by hypoxia. Our previous work has shown that 
expression of high-risk E6 and E7 can enhance the expression of angiogenic factors such 
as VEGF even in non-hypoxic conditions (177). However, it was unclear if HIF-1α 
activation was responsible. Additionally, another putative mechanism based on the EBV 
literature, is that HPV 16 E7 may interfere with the ability of prolyl hydroxylases to 
hydroxylate proline residues on HIF-1α under normoxic conditions thus stabilizing HIF-
1a. As seen in Figure 14, HPV 16 E7, as well as HPV 16 E6 or HPV 16E6E7, have no 
detectible effect on HIF-1α levels in normoxia thus suggesting that the induction of HIF-
1α occurs specifically under hypoxic conditions. Therefore, HIF-1α and HIF-2α-
independent mechanisms maybe responsible for E7-mediated activation of VEGF.  
 HIF-1α independent mechanisms have been reported responsible for the activation 
of VEGF. One possible mechanism for HPV 16 E7 ability to increase VEGF expression  
is through AP-1. E7 can transactivate AP-1 sites on the VEGF promoter (Figure 28). 
Further experiments are needed to determine how VEGF expression is regulated by E6 
and E7. 
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Figure 28. Possible Mechanism of HPV 16 E6 and 16 E7 Enhancement of VEGF. 
 (A) Negative regulation of SP-1 by p53. (B) HPV 16 E6 degradation of p53 leads 
to the enhancement of VEGF. (C) HPV 16 E7 transactivates AP-1 leading to the 
enhancement of VEGF. 
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E. Conditioned media from pooled HFKS transduced with HPV 16E6TTLE7 or  
HPV 16E6E7TTL did not induce migration of human microvascular endothelial 
cells (HMVECs) in vitro. 
 We have shown that conditioned media from cells expressing HPV 16E6TTLE7 or 
HPV 16E6E7TTL do not induce migration of HMVECs. This is in contrast to cells 
expressing HPV 16E6E7. These results are consistent with a series of transgenic 
experiments from the Lambert laboratory. Lambert et al. showed that E7 played a major 
role in promotion, an early step in tumorigenesis (158). In contrast, E6 was shown to 
contribute weakly to the promotion stage to benign disease. E6 in addition to E7 led to an 
increase in the formation of large and more invasive cancers (158). Based on the above 
data we conclude that the combination of E6 and E7 is required to induce migration of 
HMVECs which may lead to a higher grade of disease. 
 
F. VEGF, but not IL-8, is required for the increased migration of HMVECs in vitro. 
 We have shown that IL-8 depleted conditioned media from cells expressing HPV 
16E6E7 retained its ability to increase migration of HMVECs. This is in contrast to 
VEGF-depleted conditioned media from cells expressing HPV 16E6E7, which does not 
induce migration of HMVEC. There are a number of different factors within the tumor 
microenvironment that are regulators of angiogenesis (fibroblasts and mast cells), which 
combine to recruit endothelial cells from the local vasculature (130). Fibroblasts are 
known to produce VEGF. These factors in addition to VEGF and HPV16 E6 and E7 may 
result in the increase of endothelial cell migration. 
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G. Low risk HPV 6 E7 also increases IL-8 and VEGF expression 
 We have shown that conditioned media from cells expressing HPV 6 E7 increased 
the level of secreted VEGF. One possible mechanism for the increase in VEGF 
expression is through Rb family member p130. Sanseverino et al. found that VEGF and 
p130 expression were inversely correlated in endometrial cancers (145). Specifically, 
immunohistochemical staining showed low VEGF staining correlated with high 
expression of p130. Vice versa, higher levels of expression of VEGF correlated with low 
expression of p130 (145). Further examination of VEGF upregulation by HPV 6 E7 in 
normoxic conditions needs to be explored. 
 We further show conditioned media from cells expressing HPV 6 E7 increases the 
level of secreted IL-8. The mechanism for this increase remains unknown. Further 
examination of IL-8 upregulation by HPV 6 E7 needs to be explored. 
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FUTURE DIRECTIONS 
 
The work in this thesis has begun to address the contributions of E6 and E7 to an 
angiogenic switch, which is important for the development of HPV-mediated disease. 
There are a number of questions still to be answered and observations to be investigated 
because of results presented in Chapters I-III and discussed above. 
For future investigations, it is important to first study the individual contribution 
of E6 and E7 in an in vivo system. To test whether conditioned media from HPV 16 
E6TTLE7 or HPV 16E6E7TTL transduced pooled human foreskin keratinocytes (HFKs) 
could induce an angiogenic response in vivo, the Matrigel plug assays could be utilized. 
This assay is an excellent method for determining the angiogenic potential of different 
compounds and would provide valuable information on the individual role E6 and E7 in 
the recruitment of a blood supply. We have shown that neither E6 nor E7 alone is 
sufficient to induce migration of human microvascular endothelial cells (HMVECs). 
Based on those findings we predict that neither E6 nor E7 alone would be sufficient to 
elicit an angiogenic response in vivo.  
We have verified that angiogenic inducer VEGF in conditioned media from HPV 
16E6E7 expressing cells influenced migration of human microvascular endothelial cells 
(HMVECs) in vitro using neutralizing antibodies against VEGF. Further investigations 
will determine if VEGF contributes to the recruitment of a blood supply to the Matrigel 
plug. Matrigel plug assay would be used to assess whether conditioned media from HPV 
16E6E7 expressing cells depleted of VEGF could induce an angiogenic response.  
 Low-risk virus HPV 6 E7 has been shown to target p130 for degradation (191). 
VEGF and p130 expression have been shown to be inversely correlated (145). Based on 
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these findings, we hypothesized that low-risk HPV 6 E7 would able to increase 
expression of VEGF. We have preliminary data showing that HFKs expressing HPV 6 E7 
increased the levels of secreted VEGF as well as IL-8. Since there was variability 
between experiments, these experiments need to be repeated.  
 We have preliminary data showing that p130 may regulate the expression of VEGF 
as well as IL-8. The HPV 6 E7C25A mutant, can inhibit E7 binding to p130, could be 
used to determine if p130 binding is required for the increased expression of angiogenic 
inducers VEGF and IL-8.  
Finally, it needs to be investigated whether expression of E6 and E7 proteins of 
low-risk HPVs are able to alter the expression of angiogenic inducers, VEGF and IL-8 as 
well as angiogenic inhibitors, thrombospondin-1 (TSP-1) and Maspin similar to the affect 
observed upon expression of high-risk E6 and E7. Pooled HFKs would be co-infected 
with two retroviruses HPV 6 E6 and neor and the other expressing HPV 6 E7 and 
hygromycinr. This will ensure that the cells are infected with both viruses. Semi-
quantitative RT-PCR would be used to analyze VEGF, IL-8, Maspin and TSP-1 
transcripts. Conditioned media from these retrovirally-transduced cells would be 
monitored using ELISA for VEGF and IL-8 and Western blot analysis for TSP-1 and 
Maspin. To characterize the ability of conditioned media from cells expressing HPV 6 E6 
and 6 E7 to alter endothelial behavior migration assay would be used.  Additionally, the 
Matrigel plug assay would be used to assess whether conditioned media from HPV 6 
E6E7 could induce an angiogenic response.  
These experiments would provide additional mechanisms as to how angiogenesis 
is regulated in HPV-mediated disease. 
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